<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Paracetamol (acetaminophen) with or without an antiemetic for acute migraine headaches in adults - Derry, S - 2013 | Cochrane Library</title> <meta content="Paracetamol (acetaminophen) with or without an antiemetic for acute migraine headaches in adults - Derry, S - 2013 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008040.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Paracetamol (acetaminophen) with or without an antiemetic for acute migraine headaches in adults - Derry, S - 2013 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008040.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD008040.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Paracetamol (acetaminophen) with or without an antiemetic for acute migraine headaches in adults" name="citation_title"/> <meta content="Sheena Derry" name="citation_author"/> <meta content="sheena.derry@retired.ox.ac.uk" name="citation_author_email"/> <meta content="R Andrew Moore" name="citation_author"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="4" name="citation_issue"/> <meta content="10.1002/14651858.CD008040.pub3" name="citation_doi"/> <meta content="2013" name="citation_date"/> <meta content="2013/04/30" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008040.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008040.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008040.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Acetaminophen [adverse effects, *therapeutic use]; Acute Disease; Analgesics, Non‐Narcotic [adverse effects, *therapeutic use]; Antiemetics [adverse effects, *therapeutic use]; Drug Therapy, Combination [methods]; Hyperacusis [drug therapy]; Metoclopramide [adverse effects, therapeutic use]; Migraine Disorders [*drug therapy]; Photophobia [drug therapy]; Randomized Controlled Trials as Topic; Sumatriptan [adverse effects, therapeutic use]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008040.pub3&amp;doi=10.1002/14651858.CD008040.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008040.pub3&amp;doi=10.1002/14651858.CD008040.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008040.pub3&amp;doi=10.1002/14651858.CD008040.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008040.pub3&amp;doi=10.1002/14651858.CD008040.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008040.pub3&amp;doi=10.1002/14651858.CD008040.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008040.pub3&amp;doi=10.1002/14651858.CD008040.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008040.pub3&amp;doi=10.1002/14651858.CD008040.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008040.pub3&amp;doi=10.1002/14651858.CD008040.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008040.pub3&amp;doi=10.1002/14651858.CD008040.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008040.pub3&amp;doi=10.1002/14651858.CD008040.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008040.pub3&amp;doi=10.1002/14651858.CD008040.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008040.pub3&amp;doi=10.1002/14651858.CD008040.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008040.pub3&amp;doi=10.1002/14651858.CD008040.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008040.pub3&amp;doi=10.1002/14651858.CD008040.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008040.pub3&amp;doi=10.1002/14651858.CD008040.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008040.pub3&amp;doi=10.1002/14651858.CD008040.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008040.pub3&amp;doi=10.1002/14651858.CD008040.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008040.pub3&amp;doi=10.1002/14651858.CD008040.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008040.pub3&amp;doi=10.1002/14651858.CD008040.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008040.pub3&amp;doi=10.1002/14651858.CD008040.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008040.pub3&amp;doi=10.1002/14651858.CD008040.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008040.pub3&amp;doi=10.1002/14651858.CD008040.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008040.pub3&amp;doi=10.1002/14651858.CD008040.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="jiwTpTuf";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD008040\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD008040\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008040\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008040\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ru","ko","ms","fa","zh_HANS"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD008040.pub3",title:"Paracetamol (acetaminophen) with or without an antiemetic for acute migraine headaches in adults",firstPublishedDate:"Apr 30, 2013 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Pain, Palliative and Supportive Care Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=jiwTpTuf&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008040.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD008040.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD008040.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD008040.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008040.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD008040.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD008040.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD008040.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD008040.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD008040.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD008040.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD008040.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD008040.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD008040.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>4517 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD008040.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008040.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008040.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008040.pub3/full#CD008040-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008040.pub3/full#CD008040-sec-0095"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008040.pub3/full#CD008040-sec-0029"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008040.pub3/full#CD008040-sec-0030"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008040.pub3/full#CD008040-sec-0035"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008040.pub3/full#CD008040-sec-0036"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008040.pub3/full#CD008040-sec-0059"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008040.pub3/full#CD008040-sec-0089"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD008040.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008040.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008040.pub3/appendices#CD008040-sec-0100"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008040.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008040.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD008040.pub3/media/CDSR/CD008040/table_n/CD008040StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD008040.pub3/media/CDSR/CD008040/table_n/CD008040StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008040.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008040.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008040.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD008040.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD008040.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD008040.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2019 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD008040.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Paracetamol (acetaminophen) with or without an antiemetic for acute migraine headaches in adults </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008040.pub3/information#CD008040-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Sheena Derry</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008040.pub3/information#CD008040-cr-0003">R Andrew Moore</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD008040.pub3/information/en#CD008040-sec-0114">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 30 April 2013 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD008040.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD008040.pub3">https://doi.org/10.1002/14651858.CD008040.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD008040-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008040-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD008040-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD008040-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/ko#CD008040-abs-0002">한국어</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD008040-abs-0011">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD008040-abs-0001" lang="en"> <section id="CD008040-sec-0001"> <h3 class="title" id="CD008040-sec-0001">Background</h3> <p>This is an updated version of the original Cochrane review published in Issue 11, 2010 (Derry 2010). Migraine is a common, disabling condition and a burden for the individual, health services and society. Many sufferers choose not to, or are unable to, seek professional help and rely on over‐the‐counter analgesics. Co‐therapy with an antiemetic should help to reduce nausea and vomiting, which are commonly associated with migraine. </p> </section> <section id="CD008040-sec-0002"> <h3 class="title" id="CD008040-sec-0002">Objectives</h3> <p>To determine the efficacy and tolerability of paracetamol (acetaminophen), alone or in combination with an antiemetic, compared with placebo and other active interventions in the treatment of acute migraine in adults. </p> </section> <section id="CD008040-sec-0003"> <h3 class="title" id="CD008040-sec-0003">Search methods</h3> <p>We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE and the Oxford Pain Relief Database for studies through 4 October 2010 for the original review, and to 13 February 2013 for the update. Two clinical trials registers (ClinicalTrials.gov and gsk‐clinicalstudyregister.com) were also searched on both occasions. </p> </section> <section id="CD008040-sec-0004"> <h3 class="title" id="CD008040-sec-0004">Selection criteria</h3> <p>We included randomised, double‐blind, placebo‐ or active‐controlled studies using self‐administered paracetamol to treat a migraine headache episode, with at least 10 participants per treatment arm. </p> </section> <section id="CD008040-sec-0005"> <h3 class="title" id="CD008040-sec-0005">Data collection and analysis</h3> <p>Two review authors independently assessed trial quality and extracted data. Numbers of participants achieving each outcome were used to calculate relative risk and numbers needed to treat (NNT) or harm (NNH) compared with placebo or other active treatment. </p> </section> <section id="CD008040-sec-0006"> <h3 class="title" id="CD008040-sec-0006">Main results</h3> <p>Searches for the update identified one additional study for inclusion. Eleven studies (2942 participants, 5109 attacks) compared paracetamol 1000 mg, alone or in combination with an antiemetic, with placebo or other active comparators, mainly sumatriptan 100 mg. For all efficacy outcomes paracetamol was superior to placebo, with NNTs of 12 (19% response with paracetamol, 10% with placebo), 5.0 (56% response with paracetamol, 36% with placebo) and 5.2 (39% response with paracetamol, 20% with placebo) for 2‐hour pain‐free and 2‐ and 1‐hour headache relief, respectively, when medication was taken for moderate to severe pain. </p> <p>Paracetamol 1000 mg plus metoclopramide 10 mg was not significantly different from oral sumatriptan 100 mg for 2‐hour headache relief; there were no 2‐hour pain‐free data. </p> <p>Adverse event rates were similar between paracetamol and placebo, and between paracetamol plus metoclopramide and sumatriptan. No serious adverse events occurred with paracetamol alone, but more serious and/or severe adverse events occurred with sumatriptan than with the combination therapy (NNH 32). </p> </section> <section id="CD008040-sec-0007"> <h3 class="title" id="CD008040-sec-0007">Authors' conclusions</h3> <p>Paracetamol 1000 mg alone is statistically superior to placebo in the treatment of acute migraine, but the NNT of 12 for pain‐free response at two hours is inferior to at of other commonly used analgesics. Given the low cost and wide availability of paracetamol, it may be a useful first choice drug for acute migraine in those with contraindications to, or who cannot tolerate, non‐steroidal anti‐inflammatory drugs (NSAIDs) or aspirin. The addition of 10 mg metoclopramide gives short‐term efficacy equivalent to oral sumatriptan 100 mg. Adverse events with paracetamol did not differ from placebo; serious and/or severe adverse events were slightly more common with sumatriptan than with paracetamol plus metoclopramide. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD008040-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008040-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD008040-abs-0008">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD008040-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/ko#CD008040-abs-0006">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD008040-abs-0007">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/ru#CD008040-abs-0005">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD008040-abs-0012">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD008040-abs-0004" lang="en"> <h3>Paracetamol (acetaminophen) with or without an antiemetic for acute migraine in adults</h3> <p>This is an updated version of the original Cochrane review published in Issue 11, 2010 (Derry 2010). New searches identified one additional study for inclusion; this study compared paracetamol with etodolac and did not contribute to any of the analyses in the review. </p> <p>A single oral dose of paracetamol 1000 mg will reduce headache pain from moderate or severe to none by 2 hours in 1 in 5 people (19%) taking paracetamol, compared with 1 in 10 (10%) taking placebo. Pain will be reduced from moderate or severe to no worse than mild pain by 2 hours in about 1 in 2 people (56%) taking paracetamol, compared with about 1 in 3 (36%) taking placebo. Too few data were available to assess efficacy beyond 2 hours. </p> <p>Paracetamol 1000 mg plus metoclopramide 10 mg and oral sumatriptan 100 mg provide similar levels of headache relief at 2 hours. There was insufficient information to compare paracetamol, alone or in combination, with other active treatments. </p> <p>Adverse events do not differ significantly between paracetamol and placebo. Slightly more serious and/or severe adverse events occur with sumatriptan 100 mg than with paracetamol 1000 mg plus metoclopramide 10 mg. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD008040-sec-0095" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD008040-sec-0095"></div> <h3 class="title" id="CD008040-sec-0096">Implications for practice</h3> <section id="CD008040-sec-0096"> <p>For individuals who have contraindications to, or are unable to tolerate, aspirin or NSAIDs, paracetamol 1000 mg alone may be a useful first‐line treatment for migraine headaches that do not cause severe disability. In combination with metoclopramide, paracetamol may offer similar efficacy to oral sumatriptan 100 mg, but with fewer adverse events. If tolerated, other therapies, such as aspirin or ibuprofen, are effective in more individuals. </p> </section> <h3 class="title" id="CD008040-sec-0097">Implications for research</h3> <section id="CD008040-sec-0097"> <p>Studies are needed to investigate further whether the addition of an antiemetic, such as metoclopramide, to paracetamol can improve either pain relief or migraine‐associated symptoms, and also to investigate potential benefits of different dosing strategies such as treating when pain is still mild or multiple dosing regimens. Studies should assess whether efficacy at early time points is sustained. Head‐to‐head studies with active comparators, particularly other OTC medications, would allow direct comparison between treatments. Ideally these studies would include a placebo comparator for internal validity. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD008040-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD008040-sec-0029"></div> <div class="table" id="CD008040-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span><span class="table-title"></span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Paracetamol 1000 mg compared with placebo for migraine headache</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population: adults with migraine headache ‐ moderate or severe pain</b> </p> <p><b>Settings: community</b> </p> <p><b>Intervention: paracetamol 1000 mg</b> </p> <p><b>Comparison: placebo</b> </p> </td> </tr> <tr class="table-header separated"> <td align="center" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Probable outcome with<br/> intervention</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Probable outcome with<br/> comparator</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>NNT or NNH<br/> (95% CI)</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>No of studies, attacks, events</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pain free response at 2 h</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>190 in 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>100 in 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NNT 12 (7.5 to 32)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 studies, 717 attacks, 104 events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Headache relief at 2 h</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>560 in 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>360 in 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NNT 5.0 (3.7 to 7.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 studies, 717 attacks, 334 events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Headache relief at 1 h</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>390 in 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>200 in 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NNT 5.2 (3.8 to 8.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 studies, 655 attacks, 189 vents</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>At least one AE</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>180 in 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>230 in 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NNH 21 (11 to 300)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 studies, 1293 attacks, 261 events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sustained pain‐free at 24 h</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>no data</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sustained headache relief at 24 h</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>no data</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious AE</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>insufficient data</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>CI:</b> Confidence interval; <b>NNT</b> : number needed to treat; <b>NNH</b>: number needed to harm </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>1 ‐ Quality of evidence downgraded from high because of threat from potential publication bias with modest effect size and numbers of events </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD008040-sec-0030" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD008040-sec-0030"></div> <section id="CD008040-sec-0031"> <h3 class="title" id="CD008040-sec-0031">Description of the condition</h3> <p>Migraine is a common, disabling headache disorder, ranked seventh highest among specific causes of disability globally (<a href="./references#CD008040-bbs2-0068" title="SteinerTS , StovnerLJ , BirbeckGL . Migraine: the seventh disabler. Journal of Headache and Pain2013;14:1. [DOI: 10.1186/1129‐2377‐14‐1] ">Steiner 2013</a>), with considerable social and economic impact (<a href="./references#CD008040-bbs2-0038" title="HazardE , MunakataJ , BigalME , RupnowMF , LiptonRB . The burden of migraine in the United States: current and emerging perspectives on disease management and economic analysis. Value in Health2009;12(1):55‐64. [DOI: 10.1111/j.1524‐4733.2008.00404.x] ">Hazard 2009</a>). Recent surveys found a one‐year prevalence of 15% globally (<a href="./references#CD008040-bbs2-0074" title="VosT , FlaxmanAD , NaghaviM , LozanoR , MichaudC , EzzatiM , et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990‐2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet2012;380(9859):2163‐96. [DOI: 1016/S0140‐6736(12)61729‐2] ">Vos 2012</a>) and for adults in European countries (<a href="./references#CD008040-bbs2-0069" title="StovnerLJ , AndreeC . Prevalence of headache in Europe: a review for the Eurolight project. Journal of Headache and Pain2010;11(4):289‐99. [DOI: 10.1007/s10194‐010‐0217‐0] ">Stovner 2010</a>), 13% for all ages in the United States (US) (<a href="./references#CD008040-bbs2-0071" title="VictorTW , HuX , CampbellJC , BuseDC , LiptonRB . Migraine prevalence by age and sex in the United States: a life‐span study. Cephalalgia2010;30(9):1065‐72. ">Victor 2010</a>), 21% in Russia (<a href="./references#CD008040-bbs2-0016" title="AyzenbergI , KatsaravaZ , SborowskiA , ChernyshM , OsipovaV , TabeevaG , et al. The prevalence of primary headache disorders in Russia: a countrywide survey. Cephalalgia2012;32(5):373‐81. [DOI: 10.1177/0333102412438977] ">Ayzenberg 2012</a>) and 9% for adults in China (<a href="./references#CD008040-bbs2-0076" title="YuS , LiuR , ZhaoG , YangX , QiaoX , FengJ , et al. The prevalence and burden of primary headaches in China: a population‐based door‐to‐door survey. Headache2012;52(4):582‐91. [DOI: 10.1111/j.1526‐4610.2011.02061.x] ">Yu 2012</a>). Migraine is more prevalent in women than in men (by a factor of two to three), and in the age range 30 to 50 years. </p> <p>The International Headache Society (IHS) classifies two major subtypes (<a href="./references#CD008040-bbs2-0043" title="Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia2004;24 Suppl 1:1‐160. ">IHS 2004</a>). Migraine without aura is the most common subtype. It is characterised by attacks lasting 4 to 72 hours that are typically of moderate to severe pain intensity, unilateral, pulsating, aggravated by normal physical activity and associated with nausea and/or photophobia and phonophobia. Migraine with aura is characterised by reversible focal neurological symptoms that develop over a period of 5 to 20 minutes and last for less than 60 minutes, followed by headache with the features of migraine without aura. In some cases the headache may lack migrainous features or be absent altogether. </p> <p>A recent large prevalence study in the US found that over half of migraineurs had severe impairment or required bed rest during attacks. Despite this high level of disability and a strong desire for successful treatment, only a proportion of migraine sufferers seek professional advice for the treatment of attacks. The majority were not taking any preventive medication, although one‐third met guideline criteria for offering or considering it. Nearly all (98%) migraineurs used acute treatments for attacks, with 49% using over‐the‐counter (OTC) medication only, 20% using prescription medication, and 29% using both. OTC medication included aspirin, other non‐steroidal anti‐inflammatory drugs (NSAIDs), paracetamol (acetaminophen) and paracetamol with caffeine (<a href="./references#CD008040-bbs2-0017" title="BigalME , SerranoD , ReedM , LiptonRB . Chronic migraine in the population: burden, diagnosis, and satisfaction with treatment. Neurology2008;71(8):559‐66. [DOI: 10.1212/01.wnl.0000323925.29520.e7] ">Bigal 2008</a>, <a href="./references#CD008040-bbs2-0028" title="DiamondS , BigalME , SilbersteinS , LoderE , ReedM , LiptonRB . Patterns of diagnosis and acute and preventive treatment for migraine in the United States: results from the American Migraine Prevalence and Prevention study. Headache2007;47(3):355‐63. [DOI: 10.1111/j.1526‐4610.2006.00631.x] ">Diamond 2007</a>; <a href="./references#CD008040-bbs2-0051" title="LiptonRB , BigalME , DiamondM , FreitagF , ReedML , AMPP Advisory Group, et al. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology2007;68(5):343‐9. ">Lipton 2007</a>). Similar findings have been reported from other large studies in France and Germany (<a href="./references#CD008040-bbs2-0052" title="LucasC , GéraudG , ValadeD , ChautardMH , Lantéri‐MinetM . Recognition and therapeutic management of migraine in 2004, in France: results of FRAMIG 3, a French nationwide population‐based survey. Headache2006;46(5):715‐25. [DOI: 10.1111/j.1526‐4610.2006.00430.x] ">Lucas 2006</a>; <a href="./references#CD008040-bbs2-0062" title="RadtkeA , NeuhauserH . Prevalence and burden of headache and migraine in Germany. Headache2009;49(1):79‐89. [DOI: 10.1111/j.1526‐4610.2008.01263.x] ">Radtke 2009</a>). </p> <p>The significant impact of migraine with regard to pain, functional health and well‐being is well documented (<a href="./references#CD008040-bbs2-0020" title="BuseD , ManackA , SerranoD , ReedM , VaronS , TurkelC , et al. Headache impact of chronic and episodic migraine: results from the American Migraine Prevalence and Prevention study. Headache2012;52(1):3‐17. [DOI: 10.1111/j.1526‐4610.2011.02046.x] ">Buse 2011</a>; <a href="./references#CD008040-bbs2-0048" title="LeonardiM , SteinerTJ , ScherAT , LiptonRB . The global burden of migraine: measuring disability in headache disorders with WHO's Classification of Functioning, Disability and Health (ICF). Journal of Headache and Pain2005;6(6):429‐40. [DOI: 10.1007/s10194‐005‐0252‐4] ">Leonardi 2005</a>; <a href="./references#CD008040-bbs2-0074" title="VosT , FlaxmanAD , NaghaviM , LozanoR , MichaudC , EzzatiM , et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990‐2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet2012;380(9859):2163‐96. [DOI: 1016/S0140‐6736(12)61729‐2] ">Vos 2012</a>) A cross‐sectional survey of eight European U countries (representing 55% of the adult population) has estimated an annual direct and indirect cost of migraine per person of €1222, and a total annual cost for the EU of €111 billion for adults aged 18 to 65 years (<a href="./references#CD008040-bbs2-0049" title="LindeM , GustavssonA , StovnerLJ , SteinerTJ , BarréJ , KatsaravaZ , et al. The cost of headache disorders in Europe: the Eurolight project. European Journal of Neurology2012;19(5):703‐11. [DOI: 10.1111/j.1468‐1331.2011.03612.x] ">Linde 2012</a>). Costs are substantially greater for the minority with chronic migraine compared with episodic migraine; they also vary between countries, probably due to differences in available therapies and they way they are delivered, and to structural differences in healthcare systems (<a href="./references#CD008040-bbs2-0018" title="BloudekLM , StokesM , BuseDC , WilcoxTK , LiptonRB , GoadsbyPJ , et al. Cost of healthcare for patients with migraine in five European countries: results from the International Burden of Migraine Study (IBMS). Journal of Headache and Pain2012;13(5):361‐78. [DOI: 10.1007/s10194‐012‐0460‐7] ">Bloudek 2012</a>). In the US, the average annual direct cost per person has been estimated at $1757 for episodic migraine and $7750 for chronic migraine (<a href="./references#CD008040-bbs2-0056" title="MunakataJ , HazardE , SerranoD , KlingmanD , RupnowMF , TierceJ , et al. Economic burden of transformed migraine: results from the American Migraine Prevalence and Prevention (AMPP) Study. Headache2009;49(4):498‐508. [DOI: 10.1111/j.1526‐4610.2009.01369.x] ">Munakata 2009</a>). Whatever the exact direct and indirect costs are for each country, it is clear that migraine presents a significant economic burden. Successful treatment of acute migraine attacks not only benefits patients by reducing their disability and improving health‐related quality of life, but also has the potential to reduce the need for healthcare resources and increase economic productivity. Migraine is ranked in the top 10 disorders for global years lived with disability (<a href="./references#CD008040-bbs2-0074" title="VosT , FlaxmanAD , NaghaviM , LozanoR , MichaudC , EzzatiM , et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990‐2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet2012;380(9859):2163‐96. [DOI: 1016/S0140‐6736(12)61729‐2] ">Vos 2012</a>). </p> </section> <section id="CD008040-sec-0032"> <h3 class="title" id="CD008040-sec-0032">Description of the intervention</h3> <p>Paracetamol (acetaminophen) was first identified as the active metabolite of two older antipyretic drugs, acetanilide and phenacetin, in the late nineteenth century. It became available in the United Kingdom (UK) on prescription in 1956, and OTC in 1963 (<a href="./references#CD008040-bbs2-0059" title="PharmWeb . Paracetamol Information Centre. www.pharmweb.net/pwmirror/pwy/paracetamol/pharmwebpic.html (accessed 30 July 2009). ">PIC 2009</a>). Since then it has become one of the most popular antipyretic and analgesic drugs worldwide, and is often also used in combination with other drugs. OTC medications are less expensive, more accessible, and have favourable safety profiles relative to many prescription treatments. </p> <p>Despite a low incidence of adverse effects, paracetamol has a recognised potential for hepatotoxicity and is thought to be responsible for approximately half of all cases of liver failure in the UK (<a href="./references#CD008040-bbs2-0037" title="HawtonK , TownsendE , DeeksJ , ApplebyL , GunnellD , BennewithO , et al. Effects of legislation restricting pack sizes of paracetamol and salicylate on self poisoning in the United Kingdom: before and after study. BMJ2001;322(7296):1203‐7. ">Hawton 2001</a>), and about 40% in the US (<a href="./references#CD008040-bbs2-0057" title="NorrisW , ParedesAH , LewisJH . Drug‐induced liver injury in 2007. Current Opinion in Gastroenterology2008;24(3):287‐97. ">Norris 2008</a>). Acute paracetamol hepatotoxicity at therapeutic doses is extremely unlikely despite reports of so‐called therapeutic misadventure (<a href="./references#CD008040-bbs2-0060" title="PrescottLF . Therapeutic misadventure with paracetamol: fact or fiction?. American Journal of Therapeutics2000;7(2):99‐114. ">Prescott 2000</a>). In recent years legislative changes restricting pack sizes and the maximum number of tablets permitted in OTC sales were introduced in the UK (<a href="./references#CD008040-bbs2-0024" title="Committee on Safety of Medicines. Medicines Control Agency. Paracetamol and aspirin. Current Problems in Pharmacovigilance1997;23:9. ">CSM 1997</a>) on the basis of evidence that poisoning is lower in countries that restrict availability (<a href="./references#CD008040-bbs2-0035" title="GunnellD , HawtonK , GarnierV , BismuthC , FaggJ . Use of paracetamol for suicide and non‐fatal poisoning in the UK and France: are restrictions on availability justified?. Journal of Epidemiology and Community Health1997;51(2):175‐9. ">Gunnell 1997</a>; <a href="./references#CD008040-bbs2-0037" title="HawtonK , TownsendE , DeeksJ , ApplebyL , GunnellD , BennewithO , et al. Effects of legislation restricting pack sizes of paracetamol and salicylate on self poisoning in the United Kingdom: before and after study. BMJ2001;322(7296):1203‐7. ">Hawton 2001</a>). The contribution of these changes, which are inconvenient and costly (particularly to chronic pain sufferers), to any observed reductions in incidence of liver failure or death, remains uncertain (<a href="./references#CD008040-bbs2-0036" title="HawkinsLC , EdwardsJN , DarganPI . Impact of restricting paracetamol pack sizes on paracetamol poisoning in the United Kingdom: a review of the literature. Drug Safety2007;30(6):465‐79. ">Hawkins 2007</a>). There have been concerns over the safety of paracetamol in patients with compromised hepatic function (those with severe alcoholism, cirrhosis or hepatitis), but these have not been substantiated (<a href="./references#CD008040-bbs2-0025" title="DartRC , KuffnerEK , RumackBH . Treatment of pain or fever with paracetamol (acetaminophen) in the alcoholic patient: a systematic review. American Journal of Medicine2000;7(2):123‐34. ">Dart 2000</a>; <a href="./references#CD008040-bbs2-0059" title="PharmWeb . Paracetamol Information Centre. www.pharmweb.net/pwmirror/pwy/paracetamol/pharmwebpic.html (accessed 30 July 2009). ">PIC 2009</a>). </p> <p>Oral paracetamol, used appropriately, has the potential to reduce unnecessary pain in a variety of conditions. Paracetamol is the analgesic of choice for adult patients in whom salicylates or other NSAIDs are contraindicated. Such patients include about one in five asthmatics, those with salicylate allergies and those with a history of peptic ulcer. </p> <p>In order to establish whether paracetamol is an effective analgesic at a specified dose in acute migraine attacks, it is necessary to study its effects in circumstances that permit detection of pain relief. Such studies are carried out in individuals with established pain of moderate to severe intensity, using single doses of the interventions. Participants who experience an inadequate response with either placebo or active treatment are permitted to use rescue medication, and the intervention is considered to have failed in those individuals. In clinical practice, however, individuals would not normally wait until pain is of at least moderate severity, and may take a second dose of medication if the first dose does not provide adequate relief. Once analgesic efficacy is established in studies using single doses in established pain, further studies may investigate different treatment strategies and patient preferences. These are likely to include treating the migraine attack early while pain is mild, and using a low dose initially, with a second dose if response is inadequate. </p> </section> <section id="CD008040-sec-0033"> <h3 class="title" id="CD008040-sec-0033">How the intervention might work</h3> <p>The lack of significant anti‐inflammatory activity of paracetamol implies a mode of action distinct from that of NSAIDs; yet, despite years of use and research, the mechanisms of action of paracetamol are not fully understood. NSAIDs act by inhibiting the activity of cyclooxygenase (COX), now recognised to consist of two isoforms (COX‐1 and COX‐2), which catalyses the production of prostaglandins responsible for pain and inflammation. Paracetamol has previously been shown to have no significant effects on COX‐1 or COX‐2 (<a href="./references#CD008040-bbs2-0066" title="SchwabJM , SchluesenerHJ , LauferS . COX‐3: just another COX or the solitary elusive target of paracetamol?. Lancet2003;361(9362):981‐2. ">Schwab 2003</a>), but is now being considered as a selective COX‐2 inhibitor (<a href="./references#CD008040-bbs2-0040" title="HinzB , ChereminaO , BruneK . Acetaminophen (paracetamol) is a selective cyclooxygenase‐2 inhibitor in man. Federation of American Societies for Experimental Biology Journal2008;22(2):383‐90. [DOI: 10.1096/fj.07‐8506com] ">Hinz 2008</a>). Significant paracetamol‐induced inhibition of prostaglandin production has been demonstrated in tissues in the brain, spleen and lung (<a href="./references#CD008040-bbs2-0019" title="BottingRM . Mechanism of action of acetaminophen: is there a cyclooxygenase 3?. Clinical Infectious Diseases2000;31(5):S203‐S210. ">Botting 2000</a>; <a href="./references#CD008040-bbs2-0032" title="FlowerRJ , VaneJR . Inhibition of prostaglandin synthetase in brain explains the anti‐pyretic activity of paracetamol (4‐acetamidophenol). Nature1972;240(5381):410‐1. ">Flower 1972</a>). A 'COX‐3 hypothesis', wherein the efficacy of paracetamol is attributed to its specific inhibition of a third cyclooxygenase isoform enzyme, COX‐3 (<a href="./references#CD008040-bbs2-0019" title="BottingRM . Mechanism of action of acetaminophen: is there a cyclooxygenase 3?. Clinical Infectious Diseases2000;31(5):S203‐S210. ">Botting 2000</a>; <a href="./references#CD008040-bbs2-0021" title="ChandrasekharanNV . COX‐3, a cyclooxygenase‐1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure and expression. Proceedings of the National Academy of Sciences of the United States of America2002;99(21):13926‐31. ">Chandrasekharan 2002</a>), now has little credibility, and a central mode action of paracetamol is thought to be likely (<a href="./references#CD008040-bbs2-0034" title="GrahamGG , ScottKF . Mechanism of action of paracetamol. American Journal of Therapeutics2005;12(1):46‐55. [DOI: 10.1097/00045391‐200501000‐00008] ">Graham 2005</a>). </p> <p>The efficacy of oral medications is reduced in many migraineurs because of impaired gastrointestinal motility, which is associated with nausea, and because of non‐absorption of the drug due to vomiting (<a href="./references#CD008040-bbs2-0072" title="VolansGN . Absorption of effervescent aspirin during migraine. British Medical Journal1974;4(5939):265‐8. ">Volans 1974</a>). The addition of an antiemetic may improve outcomes by alleviating the often incapacitating symptoms of nausea and vomiting, and (at least potentially) by enhancing the bioavailability of the co‐administered analgesic. In particular, prokinetic antiemetics such as metoclopramide, which stimulate gastric emptying, may improve outcomes by increasing absorption of the analgesic. This has been investigated for metoclopramide and aspirin (<a href="./references#CD008040-bbs2-0064" title="Ross‐LeeLM , EadieMJ , HeazlewoodV , BochnerF , TyrerJH . Aspirin pharmacokinetics in migraine. The effect of metoclopramide. European Journal of Clinical Pharmacology1983;24(6):777‐85. ">Ross‐Lee 1983</a>; <a href="./references#CD008040-bbs2-0073" title="VolansGN . The effect of metoclopramide on the absorption of effervescent aspirin in migraine. British Journal of Clinical Pharmacology1975;2(1):57‐63. ">Volans 1975</a>). It has been claimed that treatment with intravenous metoclopramide alone can reduce pain in severe migraine (<a href="./references#CD008040-bbs2-0033" title="FriedmanBW , CorboJ , LiptonRB , BijurPE , EssesD , SolorzanoC , et al. A trial of metoclopramide vs sumatriptan for the emergency department treatment of migraines. Neurology2005;64(3):463‐8. [DOI: 10.1212/01.WNL.0000150904.28131.DD] ">Friedman 2005</a>; <a href="./references#CD008040-bbs2-0065" title="Salazar‐TortoleroG , Huertas‐CampistolA , Vergez‐PintoL , Ramos‐BrunetA , Lluch‐LópezJ . Metoclopramide as a painkiller for intense migraine headache in emergency departments [Metoclopramida como analgésicoen la cefalea migrañosa intensa en urgencias]. Revista de Neurologia2008;47(10):506‐8. ">Salazar‐Tortolero 2008</a>), but this claim requires further investigation, since metoclopramide has not been shown to be an analgesic in classical pain studies. The present review will seek to determine whether treatment of acute migraine attacks with paracetamol plus an antiemetic is in any way superior to treatment with paracetamol alone. </p> </section> <section id="CD008040-sec-0034"> <h3 class="title" id="CD008040-sec-0034">Why it is important to do this review</h3> <p>Population surveys show that paracetamol is frequently used to treat migraine headaches, but we could find no systematic review of the efficacy of this intervention in adults. It is important to know where this widely available and inexpensive drug fits in the range of therapeutic options for migraine therapy. For many migraineurs, non‐prescription therapies offer convenience, and may be the only ones available or affordable. </p> <p>This review is one of a series examining the efficacy of OTC treatments for migraine, including aspirin (<a href="./references#CD008040-bbs2-0046" title="KirthiV , DerryS , MooreRA , McQuayHJ . Aspirin with or without an antiemetic for acute migraine headaches in adults. Cochrane Database of Systematic Reviews2013, Issue 4. [DOI: 10.1002/14651858.CD008041.pub3] ">Kirthi 2013</a>) ibuprofen (<a href="./references#CD008040-bbs2-0061" title="RabbieR , DerryS , MooreRA , McQuayHJ . Ibuprofen with or without an antiemetic for acute migraine headaches in adults. Cochrane Database of Systematic Reviews2013, Issue 4. [DOI: 10.1002/14651858.CD008039.pub2] ">Rabbie 2013</a>), and diclofenac (<a href="./references#CD008040-bbs2-0027" title="DerryS , RabbieR , MooreRA . Diclofenac with or without an antiemetic for acute migraine headaches in adults. Cochrane Database of Systematic Reviews2013, Issue 4. [DOI: 10.1002/14651858.CD008783.pub3] ">Derry 2013</a>), as well as oral sumatriptan (<a href="./references#CD008040-bbs2-0026" title="DerryCJ , DerryS , MooreRA . Sumatriptan (oral route of administration) for acute migraine attacks in adults. Cochrane Database of Systematic Reviews2012, Issue 2. [DOI: 10.1002/14651858.CD008615.pub2] ">Derry 2012b</a>), which is available without prescription in some countries. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD008040-sec-0035" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD008040-sec-0035"></div> <p>The objective of the review is to determine the efficacy and tolerability of paracetamol, alone or in combination with an antiemetic, compared with placebo and other active interventions in the treatment of acute migraine headaches in adults. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD008040-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD008040-sec-0036"></div> <section id="CD008040-sec-0037"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD008040-sec-0038"> <h4 class="title">Types of studies</h4> <p>We included randomised, double blind, placebo‐ or active‐controlled studies using paracetamol to treat a migraine headache episode. Studies had to have a minimum of 10 participants per treatment arm and report dichotomous data for at least one of the outcomes specified. We accepted studies reporting treatment of consecutive headache episodes if outcomes for the first, or each, episode were reported separately. We accepted cross‐over studies if there was adequate (at least 24 hours) washout between treatments. </p> </section> <section id="CD008040-sec-0039"> <h4 class="title">Types of participants</h4> <p>Studies included adults (at least 18 years of age) with migraine. We used the definition of migraine specified by the International Headache Society (<a href="./references#CD008040-bbs2-0041" title="Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia1988;8 Suppl 7:1‐96. ">IHS 1988</a>; <a href="./references#CD008040-bbs2-0043" title="Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia2004;24 Suppl 1:1‐160. ">IHS 2004</a>), although other definitions were considered if they conformed in general to IHS diagnostic criteria. There were no restrictions on migraine frequency, duration or type (with or without aura). We accepted studies that included participants taking stable prophylactic therapy to reduce the frequency of migraine attacks. If reported, details on any prophylactic therapy prescribed or allowed are provided in the <a href="./references#CD008040-sec-0121" title="">Characteristics of included studies</a> table. </p> </section> <section id="CD008040-sec-0040"> <h4 class="title">Types of interventions</h4> <p>We included studies using a single dose of paracetamol to treat a migraine headache episode when pain was of moderate to severe intensity, or investigating different dosing strategies or timing of the first dose, or both, in relation to headache intensity. There were no restrictions on dose or route of administration, provided the medication was self‐administered. </p> <p>Included studies could use either paracetamol alone, or paracetamol plus an antiemetic. The antiemetic had to be taken either combined with paracetamol in a single formulation, or separately not more than 30 minutes before paracetamol, and had to be self‐administered. </p> <p>A placebo comparator is essential to demonstrate that paracetamol is effective in this condition. We considered active‐controlled trials without a placebo as secondary evidence. We excluded studies designed to demonstrate prophylactic efficacy in reducing the frequency of migraine attacks. </p> </section> <section id="CD008040-sec-0041"> <h4 class="title">Types of outcome measures</h4> <p>In selecting the main outcome measures for this review, we considered scientific rigour, availability of data and patient preferences (<a href="./references#CD008040-bbs2-0050" title="LiptonRB , StewartWF . Acute migraine therapy: do doctors understand what patients with migraine want from therapy?. Headache1999;39 Suppl 2:S20‐S26. ">Lipton 1999</a>). Patients with acute migraine headaches have rated complete pain relief, no headache recurrence, rapid onset of pain relief, and no side effects as the four most important outcomes (<a href="./references#CD008040-bbs2-0050" title="LiptonRB , StewartWF . Acute migraine therapy: do doctors understand what patients with migraine want from therapy?. Headache1999;39 Suppl 2:S20‐S26. ">Lipton 1999</a>). </p> <p>In view of these patient preferences, and in line with the guidelines for controlled trials of drugs in migraine issued by the IHS (<a href="./references#CD008040-bbs2-0042" title="International Headache Society Clinical Trials Subcommittee. Guidelines for controlled trials of drugs in migraine: second edition. Cephalalgia2000;20(9):765‐86. ">IHS 2000</a>), the main outcomes to be considered were: </p> <section id="CD008040-sec-0042"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD008040-list-0001"> <li> <p>Pain‐free at two hours, without the use of rescue medication (PF2).</p> </li> <li> <p>Reduction in headache pain ('headache relief') at two hours (HR2) ‐ pain reduced from moderate or severe to none or mild without the use of rescue medication. </p> </li> </ul> </p> <p>Data for pain‐free and headache relief at earlier time points were collected when reported and relevant. </p> </section> <section id="CD008040-sec-0043"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD008040-list-0002"> <li> <p>Sustained pain‐free during 24 hours (SPF24) ‐ pain‐free within two hours, with no use of rescue medication or recurrence of moderate to severe pain within 24 hours. </p> </li> <li> <p>Sustained pain reduction over 24 hours (SHR24) ‐ headache relief at two hours, sustained for 24 hours, with no use of rescue medication or second dose of study medication. </p> </li> <li> <p>Adverse events: participants with any adverse event during 24 hours postdose; serious adverse events; adverse events leading to withdrawal. </p> </li> </ul> </p> <p>Pain intensity or pain relief had to be measured by the patient (not the investigator or care provider). Pain measures accepted for the primary outcomes were: </p> <p> <ul id="CD008040-list-0003"> <li> <p>Pain intensity (PI): 4‐point categorical scale, with wording equivalent to none, mild, moderate and severe; or 100 mm visual analogue scale (VAS), where &lt; 30 mm was considered equivalent to mild or no pain and ≥ 30 mm equivalent to moderate or severe pain (<a href="./references#CD008040-bbs2-0022" title="CollinsSL , MooreRA , McQuayHJ . The visual analogue pain intensity scale: what is moderate pain in millimetres?. Pain1997;72(1‐2):95‐7. [DOI: 10.1016/S0304‐3959(97)00005‐5] ">Collins 1997</a>); </p> </li> <li> <p>Pain relief (PR): 5‐point categorical scale, with wording equivalent to none, a little, some, a lot, complete; or 100 mm VAS, where &lt; 30 mm was considered equivalent to none or a little, and ≥ 30 mm equivalent to some, a lot or complete. </p> </li> </ul> </p> <p>We considered only data obtained directly from the patient.</p> <section id="CD008040-sec-0044"> <h6 class="title">Other outcomes</h6> <p>In the earlier review we reviewed a number of other secondary outcomes.</p> <p> <ul id="CD008040-list-0004"> <li> <p>Use of rescue medication.</p> </li> <li> <p>Relief of headache‐associated symptoms.</p> </li> <li> <p>Relief of functional disability.</p> </li> </ul> </p> <p>These are not now reported in detail in Results but have been moved to an appendix (see <a href="#CD008040-sec-0118">Differences between protocol and review</a>). </p> <p>Definitions of important terms, including all measured outcomes, are provided in <a href="./appendices#CD008040-sec-0101">Appendix 1</a>. </p> </section> </section> </section> </section> <section id="CD008040-sec-0045"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD008040-sec-0046"> <h4 class="title">Electronic searches</h4> <p>The following databases were searched for the original review to 4 October 2010:</p> <p> <ul id="CD008040-list-0005"> <li> <p>The Cochrane Central Register of Controlled Trials (CENTRAL).</p> </li> <li> <p>MEDLINE (via Ovid).</p> </li> <li> <p>EMBASE (via Ovid).</p> </li> <li> <p>Oxford Pain Relief Database (<a href="./references#CD008040-bbs2-0044" title="JadadAR , CarrollD , MooreA , McQuayH . Developing a database of published reports of randomised clinical trials in pain research. Pain1996;66(2‐3):239‐46. ">Jadad 1996a</a>). </p> </li> </ul> </p> <p>For the update we searched:</p> <p> <ul id="CD008040-list-0006"> <li> <p>the Cochrane Central Register of Controlled Trials (CENTRAL) (Issue 1, 2013);</p> </li> <li> <p>MEDLINE (via Ovid) from 1 January 2010 to 13 February 2013;</p> </li> <li> <p>EMBASE (via Ovid) from 1 January 2010 to 13 February 2013.</p> </li> </ul> </p> <p>See <a href="./appendices#CD008040-sec-0102">Appendix 2</a> for the search strategy for MEDLINE, <a href="./appendices#CD008040-sec-0103">Appendix 3</a> for the search strategy for EMBASE, and <a href="./appendices#CD008040-sec-0104">Appendix 4</a> for the search strategy for CENTRAL. There were no language restrictions. </p> </section> <section id="CD008040-sec-0047"> <h4 class="title">Searching other resources</h4> <p>Reference lists of retrieved studies and review articles were searched for additional studies, as were two clinical trials databases (www.clinicaltrials.gov and www.gsk‐clinicalstudyregister.com). Grey literature and abstracts were not searched. Glaxo‐Smith Kline provided additional detail relating to two studies for which a summary of results has been published on‐line. </p> </section> </section> <section id="CD008040-sec-0048"> <h3 class="title" id="CD008040-sec-0048">Data collection and analysis</h3> <section id="CD008040-sec-0049"> <h4 class="title">Selection of studies</h4> <p>Two review authors independently carried out the searches and selected studies for inclusion. We viewed titles and abstracts of all studies identified by electronic searches on screen, and excluded any that clearly did not satisfy inclusion criteria. We read full copies of the remaining studies to identify those suitable for inclusion. Disagreements were settled by discussion with a third review author. </p> </section> <section id="CD008040-sec-0050"> <h4 class="title">Data extraction and management</h4> <p>Two review authors independently extracted data from included studies using a standard data extraction form. Disagreements were settled by discussion with a third review author. One author entered data for the original review into RevMan 5.0, and one author entered information for the update (<a href="./references#CD008040-bbs2-0063" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012. ">RevMan 2012</a>). </p> </section> <section id="CD008040-sec-0051"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>We used the Oxford Quality Score (<a href="./references#CD008040-bbs2-0045" title="JadadAR , MooreRA , CarrollD , JenkinsonC , ReynoldsDJM , GavaghanDJ , et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Controlled Clinical Trials1996;17(1):1‐12. ">Jadad 1996b</a>) as the basis for inclusion, limiting inclusion to studies that were randomised and double‐blind as a minimum. The scores for each study are reported in the '<a href="./references#CD008040-sec-0121" title="">Characteristics of included studies</a>' table. </p> <p>Two authors independently assessed risk of bias for each study, using the criteria outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD008040-bbs2-0039" title="HigginsJPT , GreenS (editors) . Chapter 8: Assessing risk of bias in included studies. In: HigginsJPT , AltmanDG , SterneJAC editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>) and adapted from those used by the Cochrane Pregnancy and Childbirth Group, with any disagreements resolved by discussion. We assessed the following for each study: </p> <p> <ol id="CD008040-list-0007"> <li> <p>Random sequence generation (checking for possible selection bias). We assessed the method used to generate the allocation sequence as: low risk of bias (any truly random process, e.g. random number table; computer random number generator); unclear risk of bias (method used to generate sequence not clearly stated). Studies using a non‐random process (e.g. odd or even date of birth; hospital or clinic record number) were excluded. </p> </li> <li> <p>Allocation concealment (checking for possible selection bias). The method used to conceal allocation to interventions before assignment determines whether intervention allocation could have been foreseen in advance of, or during recruitment, or changed after assignment. We assessed the methods as: low risk of bias (e.g. telephone or central randomisation; consecutively numbered sealed opaque envelopes); unclear risk of bias (method not clearly stated). Studies that did not conceal allocation (e.g. open list) were excluded. </p> </li> <li> <p>Blinding of outcome assessment (checking for possible detection bias). We assessed the methods used to blind study participants and outcome assessors from knowledge of which intervention a participant received. We assessed the methods as: low risk of bias (study states that it was blinded and describes the method used to achieve blinding, e.g. identical tablets; matched in appearance and smell); unclear risk of bias (study states that it was blinded but does not provide an adequate description of how it was achieved). Studies that were not double‐blind were excluded. </p> </li> <li> <p>Incomplete outcome data (checking for possible attrition bias due to the amount, nature and handling of incomplete outcome data). We assessed the methods used to deal with incomplete data as: low risk (&lt; 10% of participants provided no data without acceptable reason ‐ e.g. they were randomised but did not have a qualifying headache). Studies with high data loss were excluded. </p> </li> </ol> </p> <p>Size of study (checking for possible biases confounded by small size). We assessed studies as being at low risk of bias (≥ 200 participants per treatment arm); unclear risk of bias (50 to 199 participants per treatment arm); high risk of bias (&lt; 50 participants per treatment arm). </p> </section> <section id="CD008040-sec-0052"> <h4 class="title">Measures of treatment effect</h4> <p>We used relative risks (or 'risk ratios', RR) to establish statistical difference. We used numbers needed to treat (NNT) and pooled percentages as absolute measures of benefit or harm. </p> <p>We used the following terms to describe adverse outcomes in terms of harm or prevention of harm: </p> <p> <ul id="CD008040-list-0008"> <li> <p>When significantly fewer adverse outcomes occur with paracetamol than with control (placebo or active) we use the term 'the number needed to treat to prevent one event' (NNTp). </p> </li> <li> <p>When significantly more adverse outcomes occur with paracetamol compared with control (placebo or active) we use the term 'the number needed to harm or cause one event' (NNH). </p> </li> </ul> </p> </section> <section id="CD008040-sec-0053"> <h4 class="title">Unit of analysis issues</h4> <p>The unit of analysis was the individual patient.</p> </section> <section id="CD008040-sec-0054"> <h4 class="title">Dealing with missing data</h4> <p>The most likely source of missing data was cross‐over studies; we planned to use only first‐period data where possible, but where that was not provided, we treated the results as if they were parallel group results. Where there were substantial missing data in any study, we would comment on this and perform sensitivity analyses to investigate their effect. </p> <p>For all outcomes we carried out analyses, as far as possible, on a modified intention‐to‐treat basis, i.e. we included all participants who were randomised and received an intervention. Where sufficient information was reported, we re‐included missing data in the analyses we undertook. We would exclude data from outcomes where results from ≥ 10% of participants were missing with no acceptable reason provided or apparent. </p> </section> <section id="CD008040-sec-0055"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed heterogeneity of response rates using L'Abbé plots, a visual method for assessing differences in results of individual studies. (<a href="./references#CD008040-bbs2-0047" title="L'AbbéKA , DetskyAS , O'RourkeK . Meta‐analysis in clinical research. Annals of Internal Medicine1987;107(2):224‐33. ">L'Abbé 1987</a>). Where data could be pooled, we report the I<sup>2</sup> statistic. </p> </section> <section id="CD008040-sec-0056"> <h4 class="title">Data synthesis</h4> <p>We analysed studies using a single dose of paracetamol in established pain of at least moderate intensity separately from studies in which medication was taken before pain was well established or in which a second dose of medication was permitted. </p> <p>We calculated effect sizes and combined data for analysis only for comparisons and outcomes where there were at least two studies and 200 participants (<a href="./references#CD008040-bbs2-0053" title="MooreRA , GavaghanD , TramerMR , CollinsSL , McQuayHJ . Size is everything ‐ large amounts of information are needed to overcome random effects in estimating direction and magnitude of treatment effects. Pain1998;78(3):209‐16. [DOI: 10.1016/S0304‐3959(98)00140‐7] ">Moore 1998</a>). We calculated relative risk of benefit or harm with 95% confidence intervals (CIs) using a fixed‐effect model (<a href="./references#CD008040-bbs2-0055" title="MorrisJA , GardnerMJ . Calculating confidence intervals for relative risk, odds ratios and standardised ratios and rates. In: GardnerMJ , AltmanDG editor(s). Statistics with confidence ‐ confidence intervals and statistical guidelines. London: British Medical Journal, 1995:50‐63. ">Morris 1995</a>). NNT, NNTp and NNH with 95% CIs were calculated using the pooled number of events by the method of Cook and Sackett (<a href="./references#CD008040-bbs2-0023" title="CookRJ , SackettDL . The number needed to treat: a clinically useful measure of treatment effect. BMJ1995;310(6977):452‐4. ">Cook 1995</a>) when there was a statistically significant difference from control. A statistically significant difference from control is assumed when the 95% CI of the relative risk of benefit or harm did not include the number one. </p> <p>We used the z test to determine significant differences between NNT, NNTp and NNH for different doses of active treatment, or between groups in the sensitivity analyses (<a href="./references#CD008040-bbs2-0070" title="TramèrMR , ReynoldsDJM , MooreRA , McQuayHJ . Impact of covert duplicate results on meta‐analysis: a case study. BMJ1997;315(7109):635‐9. ">Tramer 1997</a>). </p> <p>We describe data from comparisons and outcomes with only one study or fewer than 200 participants in the text and summary tables where appropriate for information and comparison, but they are not analysed quantitatively. </p> </section> <section id="CD008040-sec-0057"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>Issues for potential subgroup analysis were dose, monotherapy or combination with an antiemetic, formulation, and route of administration. For combined treatment with an antiemetic, we planned to compare different antiemetics if there were sufficient data. </p> </section> <section id="CD008040-sec-0058"> <h4 class="title">Sensitivity analysis</h4> <p>We planned sensitivity analysis for study quality (Oxford Quality Score of 2 versus 3 or more), and for migraine type (with aura versus without aura). A minimum of two studies, with 200 participants in total, had to be available for any sensitivity analysis. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD008040-sec-0059" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD008040-sec-0059"></div> <section id="CD008040-sec-0060"> <h3 class="title">Description of studies</h3> <section id="CD008040-sec-0061"> <h4 class="title">Included studies</h4> <p>Eleven studies fulfilled the inclusion criteria for this review; nine were published in full in peer‐reviewed journals (<a href="./references#CD008040-bbs2-0001" title="DexterSL , GrahamAN , JohnstonES , RatcliffeDM , WilkinsonMI , RoseAJ . Double‐blind controlled study of paramax in the acute treatment of common and classical migraine. British Journal of Clinical Practice1985;39(10):388‐92. ">Dexter 1985</a>; <a href="./references#CD008040-bbs2-0002" title="DowsonA , BallK , HaworthD . Comparison of a fixed combination of domperidone and paracetamol (Domperamol) with sumatriptan 50 mg in moderate to severe migraine: a randomised UK primary care study. Current Medical Research and Opinion2000;16(3):190‐7. ">Dowson 2000</a>; <a href="./references#CD008040-bbs2-0003" title="FreitagF , DiamondM , DiamondS , JanssenI , RodgersA , SkobierandaF . Efficacy and tolerability of coadministration of rizatriptan and acetaminophen vs rizatriptan or acetaminophen alone for acute migraine treatment. Headache2008;48(6):921‐30. [DOI: 10.1111/j.1526‐4610.2007.01053.x] ">Freitag 2008</a>; <a href="./references#CD008040-bbs2-0006" title="HoerneckeR , DoenickeA . Treatment of migraine attacks: combination of dihydroergotamine tartrate and paracetamol in comparison with individual drugs and placebo [Behandlung des Migraneanfalls: die Kombination Dihydroergotamintartrat und Paracetamol im Vergleich zu den Einzelsubstanzen und Placebo]. Medizinische Klinik (Munich)1993;88(11):642‐8. ">Hoernecke 1993</a>; <a href="./references#CD008040-bbs2-0007" title="LiptonRB , BaggishJS , StewartWF , CodispotiJR , FuM . Efficacy and safety of acetaminophenin the treatment of migraine. Results of a randomized, double‐blind, placebo‐controlled, population‐based study. Archives of Internal Medicine2000;160(22):3486‐92. ">Lipton 2000</a>; <a href="./references#CD008040-bbs2-0008" title="MacGregorEA , WilkinsonM , BancroftK . Domperidone plus paracetamol in the treatment of migraine. Cephalalgia1993;13(2):124‐7. ">MacGregor 1993</a>; <a href="./references#CD008040-bbs2-0009" title="NørrelundN , ChristiansenLV , PlantenerS . Tolfenamic acid versus paracetamol in migraine attacks. A double‐blind study in general practice [Tolfenamsyre versus paracetamol ved migraeneanfald. En dobbeltblind undersogelse i almen praksis]. Ugeskrift for Laeger1989;151(38):2436‐8. ">Norrelund 1989</a>; <a href="./references#CD008040-bbs2-0010" title="OztürkV , ErtaşM , BaykanB , SirinH , OzgeA , The Mig‐Etol Study Group. Efficacy and safety of 400 and 800 mg etodolac vs. 1,000 mg paracetamol in acute treatment of migraine: a randomized, double‐blind, crossover, multicenter, phase III clinical trial. Pain Practice2012:Epub ahead of print. [DOI: 10.1111/j.1533‐2500.2012.00572.x] ">Oztürk 2012</a>; <a href="./references#CD008040-bbs2-0011" title="PriorMJ , CodispotiJR , FuM . A randomized, placebo‐controlled trial of acetaminophen for treatment of migraine headache. Headache2010;50(5):819‐33. [DOI: 10.1111/j.1526‐4610.2010.01638.x] ">Prior 2010</a>), and two were available as Results Summaries on the manufacturer's website (<a href="./references#CD008040-bbs2-0004" title="A double‐blind, general practice study to compare GR43175 with paracetamol and metoclopramide in the acute treatment of migraine (Original protocol). 1992. Available at: www.gsk‐clinicalstudyregister.com/. ">GL/MIG/001/92</a>; <a href="./references#CD008040-bbs2-0005" title="A double‐blind, general practice study to compare GR43175 with paracetamol and metoclopramide in the acute treatment of migraine (Amended protocol). 1992. Available at: www.gsk‐clinicalstudyregister.com/. ">GL/MIG/001A/92</a>). No further details were provided by the manufacturer for these two studies. </p> <p>All 11 studies recruited participants between 18 and 65 or 70 years of age (mean ages ranging from 33 to 49 years; one study (<a href="./references#CD008040-bbs2-0006" title="HoerneckeR , DoenickeA . Treatment of migraine attacks: combination of dihydroergotamine tartrate and paracetamol in comparison with individual drugs and placebo [Behandlung des Migraneanfalls: die Kombination Dihydroergotamintartrat und Paracetamol im Vergleich zu den Einzelsubstanzen und Placebo]. Medizinische Klinik (Munich)1993;88(11):642‐8. ">Hoernecke 1993</a>) included one participant aged 75 years). Seven studies used IHS criteria (<a href="./references#CD008040-bbs2-0041" title="Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia1988;8 Suppl 7:1‐96. ">IHS 1988</a>; <a href="./references#CD008040-bbs2-0043" title="Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia2004;24 Suppl 1:1‐160. ">IHS 2004</a>) to diagnose migraine or other criteria that we considered compatible (<a href="./references#CD008040-bbs2-0015" title="Ad Hoc Committee on the Classification of Headache, National Institute of Neurological Diseases and Blindness. Classification of headache. JAMA1962;179(9):717‐8. ">Ad Hoc 1962</a>; <a href="./references#CD008040-bbs2-0067" title="SoykaD . Diagnosis of migraine [Diagnostik der Migrane]. Deutsche Medizinische Wochenschrift1988;113(18):735‐6. ">Soyka 1988</a>); four studies (<a href="./references#CD008040-bbs2-0001" title="DexterSL , GrahamAN , JohnstonES , RatcliffeDM , WilkinsonMI , RoseAJ . Double‐blind controlled study of paramax in the acute treatment of common and classical migraine. British Journal of Clinical Practice1985;39(10):388‐92. ">Dexter 1985</a>; <a href="./references#CD008040-bbs2-0002" title="DowsonA , BallK , HaworthD . Comparison of a fixed combination of domperidone and paracetamol (Domperamol) with sumatriptan 50 mg in moderate to severe migraine: a randomised UK primary care study. Current Medical Research and Opinion2000;16(3):190‐7. ">Dowson 2000</a>; <a href="./references#CD008040-bbs2-0004" title="A double‐blind, general practice study to compare GR43175 with paracetamol and metoclopramide in the acute treatment of migraine (Original protocol). 1992. Available at: www.gsk‐clinicalstudyregister.com/. ">GL/MIG/001/92</a>; <a href="./references#CD008040-bbs2-0005" title="A double‐blind, general practice study to compare GR43175 with paracetamol and metoclopramide in the acute treatment of migraine (Amended protocol). 1992. Available at: www.gsk‐clinicalstudyregister.com/. ">GL/MIG/001A/92</a>) did not report criteria for diagnosis, and we planned to include them, with a sensitivity analysis to determine their effect on results. In fact <a href="./references#CD008040-bbs2-0001" title="DexterSL , GrahamAN , JohnstonES , RatcliffeDM , WilkinsonMI , RoseAJ . Double‐blind controlled study of paramax in the acute treatment of common and classical migraine. British Journal of Clinical Practice1985;39(10):388‐92. ">Dexter 1985</a> did not provide any usable efficacy data, and the others did not evaluate any of the same treatment comparisons as those that did report diagnostic criteria. Most studies reported a history at study entry of migraine headaches for at least six months, one year or two years, with between one attack every two months to eight attacks per month of moderate to severe intensity if untreated. Participants were most commonly recruited through attendance at specialised migraine clinics or through primary care practices, although <a href="./references#CD008040-bbs2-0007" title="LiptonRB , BaggishJS , StewartWF , CodispotiJR , FuM . Efficacy and safety of acetaminophenin the treatment of migraine. Results of a randomized, double‐blind, placebo‐controlled, population‐based study. Archives of Internal Medicine2000;160(22):3486‐92. ">Lipton 2000</a> used telephone recruitment, and <a href="./references#CD008040-bbs2-0011" title="PriorMJ , CodispotiJR , FuM . A randomized, placebo‐controlled trial of acetaminophen for treatment of migraine headache. Headache2010;50(5):819‐33. [DOI: 10.1111/j.1526‐4610.2010.01638.x] ">Prior 2010</a> used a combination of clinic patients and advertising. </p> <p>Three studies excluded people who had recently used prophylactic medication (<a href="./references#CD008040-bbs2-0001" title="DexterSL , GrahamAN , JohnstonES , RatcliffeDM , WilkinsonMI , RoseAJ . Double‐blind controlled study of paramax in the acute treatment of common and classical migraine. British Journal of Clinical Practice1985;39(10):388‐92. ">Dexter 1985</a>; <a href="./references#CD008040-bbs2-0004" title="A double‐blind, general practice study to compare GR43175 with paracetamol and metoclopramide in the acute treatment of migraine (Original protocol). 1992. Available at: www.gsk‐clinicalstudyregister.com/. ">GL/MIG/001/92</a>; <a href="./references#CD008040-bbs2-0005" title="A double‐blind, general practice study to compare GR43175 with paracetamol and metoclopramide in the acute treatment of migraine (Amended protocol). 1992. Available at: www.gsk‐clinicalstudyregister.com/. ">GL/MIG/001A/92</a>), and three permitted stable prophylactic medication, provided it remained constant (<a href="./references#CD008040-bbs2-0002" title="DowsonA , BallK , HaworthD . Comparison of a fixed combination of domperidone and paracetamol (Domperamol) with sumatriptan 50 mg in moderate to severe migraine: a randomised UK primary care study. Current Medical Research and Opinion2000;16(3):190‐7. ">Dowson 2000</a>; <a href="./references#CD008040-bbs2-0010" title="OztürkV , ErtaşM , BaykanB , SirinH , OzgeA , The Mig‐Etol Study Group. Efficacy and safety of 400 and 800 mg etodolac vs. 1,000 mg paracetamol in acute treatment of migraine: a randomized, double‐blind, crossover, multicenter, phase III clinical trial. Pain Practice2012:Epub ahead of print. [DOI: 10.1111/j.1533‐2500.2012.00572.x] ">Oztürk 2012</a>; <a href="./references#CD008040-bbs2-0011" title="PriorMJ , CodispotiJR , FuM . A randomized, placebo‐controlled trial of acetaminophen for treatment of migraine headache. Headache2010;50(5):819‐33. [DOI: 10.1111/j.1526‐4610.2010.01638.x] ">Prior 2010</a>). The implication in other studies was that prophylactic medication was not permitted. <a href="./references#CD008040-bbs2-0007" title="LiptonRB , BaggishJS , StewartWF , CodispotiJR , FuM . Efficacy and safety of acetaminophenin the treatment of migraine. Results of a randomized, double‐blind, placebo‐controlled, population‐based study. Archives of Internal Medicine2000;160(22):3486‐92. ">Lipton 2000</a> and <a href="./references#CD008040-bbs2-0011" title="PriorMJ , CodispotiJR , FuM . A randomized, placebo‐controlled trial of acetaminophen for treatment of migraine headache. Headache2010;50(5):819‐33. [DOI: 10.1111/j.1526‐4610.2010.01638.x] ">Prior 2010</a> excluded anyone who needed bed rest in at least 50% of attacks, or experienced vomiting in at least 20% of attacks, while <a href="./references#CD008040-bbs2-0010" title="OztürkV , ErtaşM , BaykanB , SirinH , OzgeA , The Mig‐Etol Study Group. Efficacy and safety of 400 and 800 mg etodolac vs. 1,000 mg paracetamol in acute treatment of migraine: a randomized, double‐blind, crossover, multicenter, phase III clinical trial. Pain Practice2012:Epub ahead of print. [DOI: 10.1111/j.1533‐2500.2012.00572.x] ">Oztürk 2012</a> excluded anyone who had severe nausea and/or vomiting for at least 25% of attacks. </p> <p>The 11 studies reported on 14 different treatment comparisons:</p> <p> <ul id="CD008040-list-0009"> <li> <p>Four studies compared paracetamol 1000 mg alone with placebo (<a href="./references#CD008040-bbs2-0003" title="FreitagF , DiamondM , DiamondS , JanssenI , RodgersA , SkobierandaF . Efficacy and tolerability of coadministration of rizatriptan and acetaminophen vs rizatriptan or acetaminophen alone for acute migraine treatment. Headache2008;48(6):921‐30. [DOI: 10.1111/j.1526‐4610.2007.01053.x] ">Freitag 2008</a>; <a href="./references#CD008040-bbs2-0006" title="HoerneckeR , DoenickeA . Treatment of migraine attacks: combination of dihydroergotamine tartrate and paracetamol in comparison with individual drugs and placebo [Behandlung des Migraneanfalls: die Kombination Dihydroergotamintartrat und Paracetamol im Vergleich zu den Einzelsubstanzen und Placebo]. Medizinische Klinik (Munich)1993;88(11):642‐8. ">Hoernecke 1993</a>; <a href="./references#CD008040-bbs2-0007" title="LiptonRB , BaggishJS , StewartWF , CodispotiJR , FuM . Efficacy and safety of acetaminophenin the treatment of migraine. Results of a randomized, double‐blind, placebo‐controlled, population‐based study. Archives of Internal Medicine2000;160(22):3486‐92. ">Lipton 2000</a>; <a href="./references#CD008040-bbs2-0011" title="PriorMJ , CodispotiJR , FuM . A randomized, placebo‐controlled trial of acetaminophen for treatment of migraine headache. Headache2010;50(5):819‐33. [DOI: 10.1111/j.1526‐4610.2010.01638.x] ">Prior 2010</a>; 1293 participants in the comparison). </p> </li> <li> <p>One study compared paracetamol 500 mg plus the antiemetic metoclopramide 5 mg with placebo, but did not provide any usable efficacy data (<a href="./references#CD008040-bbs2-0001" title="DexterSL , GrahamAN , JohnstonES , RatcliffeDM , WilkinsonMI , RoseAJ . Double‐blind controlled study of paramax in the acute treatment of common and classical migraine. British Journal of Clinical Practice1985;39(10):388‐92. ">Dexter 1985</a>; 47 participants). </p> </li> <li> <p>One study compared paracetamol 1000 mg plus a different antiemetic, domperidone 20 mg or 30 mg, with paracetamol 1000 mg alone (<a href="./references#CD008040-bbs2-0008" title="MacGregorEA , WilkinsonM , BancroftK . Domperidone plus paracetamol in the treatment of migraine. Cephalalgia1993;13(2):124‐7. ">MacGregor 1993</a>; 46 participants in a cross‐over study). </p> </li> <li> <p>Two studies compared paracetamol 1000 mg plus metoclopramide 10 mg with sumatriptan 100 mg (<a href="./references#CD008040-bbs2-0004" title="A double‐blind, general practice study to compare GR43175 with paracetamol and metoclopramide in the acute treatment of migraine (Original protocol). 1992. Available at: www.gsk‐clinicalstudyregister.com/. ">GL/MIG/001/92</a>; <a href="./references#CD008040-bbs2-0005" title="A double‐blind, general practice study to compare GR43175 with paracetamol and metoclopramide in the acute treatment of migraine (Amended protocol). 1992. Available at: www.gsk‐clinicalstudyregister.com/. ">GL/MIG/001A/92</a>; 721 participants). </p> </li> <li> <p>One study compared paracetamol 1000 mg plus domperidone 20 mg with sumatriptan 50 mg (<a href="./references#CD008040-bbs2-0002" title="DowsonA , BallK , HaworthD . Comparison of a fixed combination of domperidone and paracetamol (Domperamol) with sumatriptan 50 mg in moderate to severe migraine: a randomised UK primary care study. Current Medical Research and Opinion2000;16(3):190‐7. ">Dowson 2000</a>; 120 participants in a cross‐over study). </p> </li> <li> <p>One study compared paracetamol 1000 mg plus dihydroergotamine 2 mg with paracetamol 1000 mg alone and with dihydroergotamine 2 mg alone (<a href="./references#CD008040-bbs2-0006" title="HoerneckeR , DoenickeA . Treatment of migraine attacks: combination of dihydroergotamine tartrate and paracetamol in comparison with individual drugs and placebo [Behandlung des Migraneanfalls: die Kombination Dihydroergotamintartrat und Paracetamol im Vergleich zu den Einzelsubstanzen und Placebo]. Medizinische Klinik (Munich)1993;88(11):642‐8. ">Hoernecke 1993</a>; 288 participants in a cross‐over study). </p> </li> <li> <p>One study compared paracetamol 1000 mg plus rizatriptan 10 mg with paracetamol 1000 mg alone and rizatriptan 10 mg alone (<a href="./references#CD008040-bbs2-0003" title="FreitagF , DiamondM , DiamondS , JanssenI , RodgersA , SkobierandaF . Efficacy and tolerability of coadministration of rizatriptan and acetaminophen vs rizatriptan or acetaminophen alone for acute migraine treatment. Headache2008;48(6):921‐30. [DOI: 10.1111/j.1526‐4610.2007.01053.x] ">Freitag 2008</a>; 173 participants). </p> </li> <li> <p>One study compared paracetamol 1000 mg with tolfenamic acid 400 mg (<a href="./references#CD008040-bbs2-0009" title="NørrelundN , ChristiansenLV , PlantenerS . Tolfenamic acid versus paracetamol in migraine attacks. A double‐blind study in general practice [Tolfenamsyre versus paracetamol ved migraeneanfald. En dobbeltblind undersogelse i almen praksis]. Ugeskrift for Laeger1989;151(38):2436‐8. ">Norrelund 1989</a>; 116 participants in a cross‐over study). </p> </li> <li> <p>One study compared paracetamol 1000 mg with etodolac 400 mg and etodolac 800 mg (<a href="./references#CD008040-bbs2-0010" title="OztürkV , ErtaşM , BaykanB , SirinH , OzgeA , The Mig‐Etol Study Group. Efficacy and safety of 400 and 800 mg etodolac vs. 1,000 mg paracetamol in acute treatment of migraine: a randomized, double‐blind, crossover, multicenter, phase III clinical trial. Pain Practice2012:Epub ahead of print. [DOI: 10.1111/j.1533‐2500.2012.00572.x] ">Oztürk 2012</a>; 173 participants in a cross‐over study). </p> </li> </ul> </p> <p>All treatments were administered orally, either at the onset of an attack when pain intensity was usually still mild (<a href="./references#CD008040-bbs2-0001" title="DexterSL , GrahamAN , JohnstonES , RatcliffeDM , WilkinsonMI , RoseAJ . Double‐blind controlled study of paramax in the acute treatment of common and classical migraine. British Journal of Clinical Practice1985;39(10):388‐92. ">Dexter 1985</a>; <a href="./references#CD008040-bbs2-0006" title="HoerneckeR , DoenickeA . Treatment of migraine attacks: combination of dihydroergotamine tartrate and paracetamol in comparison with individual drugs and placebo [Behandlung des Migraneanfalls: die Kombination Dihydroergotamintartrat und Paracetamol im Vergleich zu den Einzelsubstanzen und Placebo]. Medizinische Klinik (Munich)1993;88(11):642‐8. ">Hoernecke 1993</a>; <a href="./references#CD008040-bbs2-0008" title="MacGregorEA , WilkinsonM , BancroftK . Domperidone plus paracetamol in the treatment of migraine. Cephalalgia1993;13(2):124‐7. ">MacGregor 1993</a>; <a href="./references#CD008040-bbs2-0009" title="NørrelundN , ChristiansenLV , PlantenerS . Tolfenamic acid versus paracetamol in migraine attacks. A double‐blind study in general practice [Tolfenamsyre versus paracetamol ved migraeneanfald. En dobbeltblind undersogelse i almen praksis]. Ugeskrift for Laeger1989;151(38):2436‐8. ">Norrelund 1989</a>), or when pain intensity was moderate or severe (<a href="./references#CD008040-bbs2-0002" title="DowsonA , BallK , HaworthD . Comparison of a fixed combination of domperidone and paracetamol (Domperamol) with sumatriptan 50 mg in moderate to severe migraine: a randomised UK primary care study. Current Medical Research and Opinion2000;16(3):190‐7. ">Dowson 2000</a>; <a href="./references#CD008040-bbs2-0003" title="FreitagF , DiamondM , DiamondS , JanssenI , RodgersA , SkobierandaF . Efficacy and tolerability of coadministration of rizatriptan and acetaminophen vs rizatriptan or acetaminophen alone for acute migraine treatment. Headache2008;48(6):921‐30. [DOI: 10.1111/j.1526‐4610.2007.01053.x] ">Freitag 2008</a>; <a href="./references#CD008040-bbs2-0004" title="A double‐blind, general practice study to compare GR43175 with paracetamol and metoclopramide in the acute treatment of migraine (Original protocol). 1992. Available at: www.gsk‐clinicalstudyregister.com/. ">GL/MIG/001/92</a>; <a href="./references#CD008040-bbs2-0005" title="A double‐blind, general practice study to compare GR43175 with paracetamol and metoclopramide in the acute treatment of migraine (Amended protocol). 1992. Available at: www.gsk‐clinicalstudyregister.com/. ">GL/MIG/001A/92</a>; <a href="./references#CD008040-bbs2-0007" title="LiptonRB , BaggishJS , StewartWF , CodispotiJR , FuM . Efficacy and safety of acetaminophenin the treatment of migraine. Results of a randomized, double‐blind, placebo‐controlled, population‐based study. Archives of Internal Medicine2000;160(22):3486‐92. ">Lipton 2000</a>; <a href="./references#CD008040-bbs2-0010" title="OztürkV , ErtaşM , BaykanB , SirinH , OzgeA , The Mig‐Etol Study Group. Efficacy and safety of 400 and 800 mg etodolac vs. 1,000 mg paracetamol in acute treatment of migraine: a randomized, double‐blind, crossover, multicenter, phase III clinical trial. Pain Practice2012:Epub ahead of print. [DOI: 10.1111/j.1533‐2500.2012.00572.x] ">Oztürk 2012</a>; <a href="./references#CD008040-bbs2-0011" title="PriorMJ , CodispotiJR , FuM . A randomized, placebo‐controlled trial of acetaminophen for treatment of migraine headache. Headache2010;50(5):819‐33. [DOI: 10.1111/j.1526‐4610.2010.01638.x] ">Prior 2010</a>). Six studies used a parallel‐group design (<a href="./references#CD008040-bbs2-0001" title="DexterSL , GrahamAN , JohnstonES , RatcliffeDM , WilkinsonMI , RoseAJ . Double‐blind controlled study of paramax in the acute treatment of common and classical migraine. British Journal of Clinical Practice1985;39(10):388‐92. ">Dexter 1985</a>; <a href="./references#CD008040-bbs2-0003" title="FreitagF , DiamondM , DiamondS , JanssenI , RodgersA , SkobierandaF . Efficacy and tolerability of coadministration of rizatriptan and acetaminophen vs rizatriptan or acetaminophen alone for acute migraine treatment. Headache2008;48(6):921‐30. [DOI: 10.1111/j.1526‐4610.2007.01053.x] ">Freitag 2008</a>; <a href="./references#CD008040-bbs2-0004" title="A double‐blind, general practice study to compare GR43175 with paracetamol and metoclopramide in the acute treatment of migraine (Original protocol). 1992. Available at: www.gsk‐clinicalstudyregister.com/. ">GL/MIG/001/92</a>; <a href="./references#CD008040-bbs2-0005" title="A double‐blind, general practice study to compare GR43175 with paracetamol and metoclopramide in the acute treatment of migraine (Amended protocol). 1992. Available at: www.gsk‐clinicalstudyregister.com/. ">GL/MIG/001A/92</a>; <a href="./references#CD008040-bbs2-0007" title="LiptonRB , BaggishJS , StewartWF , CodispotiJR , FuM . Efficacy and safety of acetaminophenin the treatment of migraine. Results of a randomized, double‐blind, placebo‐controlled, population‐based study. Archives of Internal Medicine2000;160(22):3486‐92. ">Lipton 2000</a>; <a href="./references#CD008040-bbs2-0011" title="PriorMJ , CodispotiJR , FuM . A randomized, placebo‐controlled trial of acetaminophen for treatment of migraine headache. Headache2010;50(5):819‐33. [DOI: 10.1111/j.1526‐4610.2010.01638.x] ">Prior 2010</a>) and the remainder a cross‐over design. None of the cross‐over studies reported data for the first attack only, and in four (<a href="./references#CD008040-bbs2-0002" title="DowsonA , BallK , HaworthD . Comparison of a fixed combination of domperidone and paracetamol (Domperamol) with sumatriptan 50 mg in moderate to severe migraine: a randomised UK primary care study. Current Medical Research and Opinion2000;16(3):190‐7. ">Dowson 2000</a>; <a href="./references#CD008040-bbs2-0008" title="MacGregorEA , WilkinsonM , BancroftK . Domperidone plus paracetamol in the treatment of migraine. Cephalalgia1993;13(2):124‐7. ">MacGregor 1993</a>; <a href="./references#CD008040-bbs2-0009" title="NørrelundN , ChristiansenLV , PlantenerS . Tolfenamic acid versus paracetamol in migraine attacks. A double‐blind study in general practice [Tolfenamsyre versus paracetamol ved migraeneanfald. En dobbeltblind undersogelse i almen praksis]. Ugeskrift for Laeger1989;151(38):2436‐8. ">Norrelund 1989</a>; <a href="./references#CD008040-bbs2-0010" title="OztürkV , ErtaşM , BaykanB , SirinH , OzgeA , The Mig‐Etol Study Group. Efficacy and safety of 400 and 800 mg etodolac vs. 1,000 mg paracetamol in acute treatment of migraine: a randomized, double‐blind, crossover, multicenter, phase III clinical trial. Pain Practice2012:Epub ahead of print. [DOI: 10.1111/j.1533‐2500.2012.00572.x] ">Oztürk 2012</a>) the attrition rate was 20% to 25%, while in another (<a href="./references#CD008040-bbs2-0006" title="HoerneckeR , DoenickeA . Treatment of migraine attacks: combination of dihydroergotamine tartrate and paracetamol in comparison with individual drugs and placebo [Behandlung des Migraneanfalls: die Kombination Dihydroergotamintartrat und Paracetamol im Vergleich zu den Einzelsubstanzen und Placebo]. Medizinische Klinik (Munich)1993;88(11):642‐8. ">Hoernecke 1993</a>) only the number completing all four attacks was reported (completer analysis). Some participants would have been excluded because they did not experience the requisite number of qualifying headaches in the specified study period; none of the studies contributed to meta‐analyses of efficacy data. </p> <p>Most studies used a particular medication to treat a single attack (participants in cross‐over studies treated each attack with a different medication), but four studies treated three (<a href="./references#CD008040-bbs2-0004" title="A double‐blind, general practice study to compare GR43175 with paracetamol and metoclopramide in the acute treatment of migraine (Original protocol). 1992. Available at: www.gsk‐clinicalstudyregister.com/. ">GL/MIG/001/92</a>; <a href="./references#CD008040-bbs2-0005" title="A double‐blind, general practice study to compare GR43175 with paracetamol and metoclopramide in the acute treatment of migraine (Amended protocol). 1992. Available at: www.gsk‐clinicalstudyregister.com/. ">GL/MIG/001A/92</a>; <a href="./references#CD008040-bbs2-0010" title="OztürkV , ErtaşM , BaykanB , SirinH , OzgeA , The Mig‐Etol Study Group. Efficacy and safety of 400 and 800 mg etodolac vs. 1,000 mg paracetamol in acute treatment of migraine: a randomized, double‐blind, crossover, multicenter, phase III clinical trial. Pain Practice2012:Epub ahead of print. [DOI: 10.1111/j.1533‐2500.2012.00572.x] ">Oztürk 2012</a>) or four (<a href="./references#CD008040-bbs2-0001" title="DexterSL , GrahamAN , JohnstonES , RatcliffeDM , WilkinsonMI , RoseAJ . Double‐blind controlled study of paramax in the acute treatment of common and classical migraine. British Journal of Clinical Practice1985;39(10):388‐92. ">Dexter 1985</a>) attacks with the same medication. <a href="./references#CD008040-bbs2-0004" title="A double‐blind, general practice study to compare GR43175 with paracetamol and metoclopramide in the acute treatment of migraine (Original protocol). 1992. Available at: www.gsk‐clinicalstudyregister.com/. ">GL/MIG/001/92</a> and <a href="./references#CD008040-bbs2-0005" title="A double‐blind, general practice study to compare GR43175 with paracetamol and metoclopramide in the acute treatment of migraine (Amended protocol). 1992. Available at: www.gsk‐clinicalstudyregister.com/. ">GL/MIG/001A/92</a> reported data separately for each attack, and first attack data are used for the primary analysis. <a href="./references#CD008040-bbs2-0001" title="DexterSL , GrahamAN , JohnstonES , RatcliffeDM , WilkinsonMI , RoseAJ . Double‐blind controlled study of paramax in the acute treatment of common and classical migraine. British Journal of Clinical Practice1985;39(10):388‐92. ">Dexter 1985</a> did not provide any usable data for the primary analysis, and <a href="./references#CD008040-bbs2-0010" title="OztürkV , ErtaşM , BaykanB , SirinH , OzgeA , The Mig‐Etol Study Group. Efficacy and safety of 400 and 800 mg etodolac vs. 1,000 mg paracetamol in acute treatment of migraine: a randomized, double‐blind, crossover, multicenter, phase III clinical trial. Pain Practice2012:Epub ahead of print. [DOI: 10.1111/j.1533‐2500.2012.00572.x] ">Oztürk 2012</a> reported data for up to three attacks per treatment period/intervention, but did not contribute data to any analyses. </p> </section> <section id="CD008040-sec-0062"> <h4 class="title">Excluded studies</h4> <p>Three studies were excluded after reading the full paper (<a href="./references#CD008040-bbs2-0012" title="DiamondS . Treatment of migraine with isometheptene, acetaminophen, and dichloralphenazone combination: a double‐blind, crossover trial. Headache1976;15(4):282‐7. ">Diamond 1976</a>; <a href="./references#CD008040-bbs2-0013" title="DienerHC , PfaffenrathV , PagelerL , PeilH , AicherB . The fixed combination of acetylsalicylic acid, paracetamol and caffeine is more effective than single substances and dual combination for the treatment of headache: a multicentre, randomized, double‐blind, single‐dose, placebo‐controlled parallel group study. Cephalalgia2005;25(10):776‐87. [DOI: 10.1111/j.1468‐2982.2005.00948.x] ">Diener 2005</a>; <a href="./references#CD008040-bbs2-0014" title="LarsenBH , ChristiansenLV , AndersenB , OlesenJ . Randomized double‐blind comparison of tolfenamic acid and paracetamol in migraine. Acta Neurologica Scandinavica1990;81(5):464‐7. ">Larsen 1990</a>). Details are provided in the <a href="./references#CD008040-sec-0122" title="">Characteristics of excluded studies</a> table. </p> </section> </section> <section id="CD008040-sec-0063"> <h3 class="title">Risk of bias in included studies</h3> <p>Studies were of good methodological quality, with six scoring 5/5, three scoring 4/5, and two scoring 3/5 on the Oxford Quality Scale. Points were lost primarily due to failure to adequately describe the methods of randomisation and blinding, but one study <a href="./references#CD008040-bbs2-0010" title="OztürkV , ErtaşM , BaykanB , SirinH , OzgeA , The Mig‐Etol Study Group. Efficacy and safety of 400 and 800 mg etodolac vs. 1,000 mg paracetamol in acute treatment of migraine: a randomized, double‐blind, crossover, multicenter, phase III clinical trial. Pain Practice2012:Epub ahead of print. [DOI: 10.1111/j.1533‐2500.2012.00572.x] ">Oztürk 2012</a> did not adequately account for drop outs. </p> <p>A Risk of bias table was completed for randomisation, allocation concealment, blinding, incomplete outcome assessment, and size. Only three studies adequately reported allocation concealment (<a href="./references#CD008040-bbs2-0004" title="A double‐blind, general practice study to compare GR43175 with paracetamol and metoclopramide in the acute treatment of migraine (Original protocol). 1992. Available at: www.gsk‐clinicalstudyregister.com/. ">GL/MIG/001/92</a>; <a href="./references#CD008040-bbs2-0005" title="A double‐blind, general practice study to compare GR43175 with paracetamol and metoclopramide in the acute treatment of migraine (Amended protocol). 1992. Available at: www.gsk‐clinicalstudyregister.com/. ">GL/MIG/001A/92</a>; <a href="./references#CD008040-bbs2-0007" title="LiptonRB , BaggishJS , StewartWF , CodispotiJR , FuM . Efficacy and safety of acetaminophenin the treatment of migraine. Results of a randomized, double‐blind, placebo‐controlled, population‐based study. Archives of Internal Medicine2000;160(22):3486‐92. ">Lipton 2000</a>; <a href="./references#CD008040-bbs2-0011" title="PriorMJ , CodispotiJR , FuM . A randomized, placebo‐controlled trial of acetaminophen for treatment of migraine headache. Headache2010;50(5):819‐33. [DOI: 10.1111/j.1526‐4610.2010.01638.x] ">Prior 2010</a>), two were considered at high risk of bias due to incomplete outcome assessment (<a href="./references#CD008040-bbs2-0001" title="DexterSL , GrahamAN , JohnstonES , RatcliffeDM , WilkinsonMI , RoseAJ . Double‐blind controlled study of paramax in the acute treatment of common and classical migraine. British Journal of Clinical Practice1985;39(10):388‐92. ">Dexter 1985</a>; <a href="./references#CD008040-bbs2-0008" title="MacGregorEA , WilkinsonM , BancroftK . Domperidone plus paracetamol in the treatment of migraine. Cephalalgia1993;13(2):124‐7. ">MacGregor 1993</a>, and three were considered at high risk due to small size (<a href="./references#CD008040-bbs2-0001" title="DexterSL , GrahamAN , JohnstonES , RatcliffeDM , WilkinsonMI , RoseAJ . Double‐blind controlled study of paramax in the acute treatment of common and classical migraine. British Journal of Clinical Practice1985;39(10):388‐92. ">Dexter 1985</a>; <a href="./references#CD008040-bbs2-0003" title="FreitagF , DiamondM , DiamondS , JanssenI , RodgersA , SkobierandaF . Efficacy and tolerability of coadministration of rizatriptan and acetaminophen vs rizatriptan or acetaminophen alone for acute migraine treatment. Headache2008;48(6):921‐30. [DOI: 10.1111/j.1526‐4610.2007.01053.x] ">Freitag 2008</a>; <a href="./references#CD008040-bbs2-0008" title="MacGregorEA , WilkinsonM , BancroftK . Domperidone plus paracetamol in the treatment of migraine. Cephalalgia1993;13(2):124‐7. ">MacGregor 1993</a>) (<a href="#CD008040-fig-0001">Figure 1</a>). <a href="./references#CD008040-bbs2-0001" title="DexterSL , GrahamAN , JohnstonES , RatcliffeDM , WilkinsonMI , RoseAJ . Double‐blind controlled study of paramax in the acute treatment of common and classical migraine. British Journal of Clinical Practice1985;39(10):388‐92. ">Dexter 1985</a> and <a href="./references#CD008040-bbs2-0008" title="MacGregorEA , WilkinsonM , BancroftK . Domperidone plus paracetamol in the treatment of migraine. Cephalalgia1993;13(2):124‐7. ">MacGregor 1993</a> did not contribute to any pooled analyses in this review. </p> <div class="figure" id="CD008040-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies." data-id="CD008040-fig-0001" src="/cdsr/doi/10.1002/14651858.CD008040.pub3/media/CDSR/CD008040/image_n/nCD008040-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies. </p> </div> </div> </div> <p>Five studies used a cross‐over design. None reported data for the first phase separately, and three (<a href="./references#CD008040-bbs2-0002" title="DowsonA , BallK , HaworthD . Comparison of a fixed combination of domperidone and paracetamol (Domperamol) with sumatriptan 50 mg in moderate to severe migraine: a randomised UK primary care study. Current Medical Research and Opinion2000;16(3):190‐7. ">Dowson 2000</a>; <a href="./references#CD008040-bbs2-0006" title="HoerneckeR , DoenickeA . Treatment of migraine attacks: combination of dihydroergotamine tartrate and paracetamol in comparison with individual drugs and placebo [Behandlung des Migraneanfalls: die Kombination Dihydroergotamintartrat und Paracetamol im Vergleich zu den Einzelsubstanzen und Placebo]. Medizinische Klinik (Munich)1993;88(11):642‐8. ">Hoernecke 1993</a>; <a href="./references#CD008040-bbs2-0009" title="NørrelundN , ChristiansenLV , PlantenerS . Tolfenamic acid versus paracetamol in migraine attacks. A double‐blind study in general practice [Tolfenamsyre versus paracetamol ved migraeneanfald. En dobbeltblind undersogelse i almen praksis]. Ugeskrift for Laeger1989;151(38):2436‐8. ">Norrelund 1989</a>) reported only on participants who took each of the study medications. Two cross‐over studies excluded significant (&gt; 10%) numbers of participants because they did not treat attacks with each study medication; <a href="./references#CD008040-bbs2-0002" title="DowsonA , BallK , HaworthD . Comparison of a fixed combination of domperidone and paracetamol (Domperamol) with sumatriptan 50 mg in moderate to severe migraine: a randomised UK primary care study. Current Medical Research and Opinion2000;16(3):190‐7. ">Dowson 2000</a> excluded 41/161 (25%) participants, and <a href="./references#CD008040-bbs2-0006" title="HoerneckeR , DoenickeA . Treatment of migraine attacks: combination of dihydroergotamine tartrate and paracetamol in comparison with individual drugs and placebo [Behandlung des Migraneanfalls: die Kombination Dihydroergotamintartrat und Paracetamol im Vergleich zu den Einzelsubstanzen und Placebo]. Medizinische Klinik (Munich)1993;88(11):642‐8. ">Hoernecke 1993</a> excluded 186/474 (39%) participants, mostly because they did not report four separate attacks. While this is a significant loss of data from these studies, there is no reason to think that there was any systematic bias involved. Neither study contributed data to any pooled analysis. <a href="./references#CD008040-bbs2-0008" title="MacGregorEA , WilkinsonM , BancroftK . Domperidone plus paracetamol in the treatment of migraine. Cephalalgia1993;13(2):124‐7. ">MacGregor 1993</a> did not exclude two participants who had invalid data for two of three treatments. <a href="./references#CD008040-bbs2-0010" title="OztürkV , ErtaşM , BaykanB , SirinH , OzgeA , The Mig‐Etol Study Group. Efficacy and safety of 400 and 800 mg etodolac vs. 1,000 mg paracetamol in acute treatment of migraine: a randomized, double‐blind, crossover, multicenter, phase III clinical trial. Pain Practice2012:Epub ahead of print. [DOI: 10.1111/j.1533‐2500.2012.00572.x] ">Oztürk 2012</a> reported combined data for up to three attacks treated with each of three interventions, but did not comment on numbers of participants who did not experience three attacks per treatment or otherwise explain drop‐outs. </p> </section> <section id="CD008040-sec-0064"> <h3 class="title" id="CD008040-sec-0064">Effects of interventions</h3> <p>See: <a href="./full#CD008040-tbl-0001"><b>Summary of findings for the main comparison</b> </a> </p> <p>Although 11 studies were identified for inclusion in this review, few compared paracetamol, with or without an antiemetic, with either placebo or the same active comparator, when taken either at onset of pain (while pain intensity was usually mild) or once pain intensity was moderate or severe. Consequently, few studies could be combined, and there were few data available for meta‐analysis. We have reported on all comparisons with at least 200 participants and have analysed quantitatively all those involving at least two studies and 200 participants or treated attacks. </p> <p>Details of outcomes in individual studies are provided in <a href="./appendices#CD008040-sec-0105">Appendix 5</a> (efficacy) and <a href="./appendices#CD008040-sec-0106">Appendix 6</a> (adverse events and withdrawals). </p> <p>Results for the primary analyses are summarised in Summary of results A.</p> <section id="CD008040-sec-0065"> <h4 class="title">Pain‐free at two hours</h4> <section id="CD008040-sec-0066"> <h5 class="title">Paracetamol 1000 mg versus placebo</h5> <p>Three studies (717 participants) provided data for pain‐free response at two hours when medication was taken for moderate to severe pain (<a href="./references#CD008040-bbs2-0003" title="FreitagF , DiamondM , DiamondS , JanssenI , RodgersA , SkobierandaF . Efficacy and tolerability of coadministration of rizatriptan and acetaminophen vs rizatriptan or acetaminophen alone for acute migraine treatment. Headache2008;48(6):921‐30. [DOI: 10.1111/j.1526‐4610.2007.01053.x] ">Freitag 2008</a>; <a href="./references#CD008040-bbs2-0007" title="LiptonRB , BaggishJS , StewartWF , CodispotiJR , FuM . Efficacy and safety of acetaminophenin the treatment of migraine. Results of a randomized, double‐blind, placebo‐controlled, population‐based study. Archives of Internal Medicine2000;160(22):3486‐92. ">Lipton 2000</a>; <a href="./references#CD008040-bbs2-0011" title="PriorMJ , CodispotiJR , FuM . A randomized, placebo‐controlled trial of acetaminophen for treatment of migraine headache. Headache2010;50(5):819‐33. [DOI: 10.1111/j.1526‐4610.2010.01638.x] ">Prior 2010</a>). </p> <p> <ul id="CD008040-list-0010"> <li> <p>The proportion of participants pain‐free at two hours with paracetamol 1000 mg was 19% (68/367; range 14% to 26%). </p> </li> <li> <p>The proportion of participants pain‐free at two hours with placebo was 10% (36/350; range 8% to 15%). </p> </li> <li> <p>The relative benefit of treatment compared with placebo was 1.8 (95% CI 1.2 to 2.6); the NNT was 12 (7.5 to 32) (<a href="./references#CD008040-fig-0004" title="">Analysis 1.1</a>; <a href="#CD008040-fig-0002">Figure 2</a>). </p> </li> </ul> </p> <div class="figure" id="CD008040-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Paracetamol 1000 mg versus placebo, outcome: 1.1 Pain‐free at 2 hours." data-id="CD008040-fig-0002" src="/cdsr/doi/10.1002/14651858.CD008040.pub3/media/CDSR/CD008040/image_n/nCD008040-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Paracetamol 1000 mg versus placebo, outcome: 1.1 Pain‐free at 2 hours. </p> </div> </div> </div> <p>One other study (576 attacks) provided data equivalent to pain‐free response at two hours (pain 0 or 1 on scale 0 to 9) when medication was taken at the onset of attack and the pain not necessarily moderate or severe (<a href="./references#CD008040-bbs2-0006" title="HoerneckeR , DoenickeA . Treatment of migraine attacks: combination of dihydroergotamine tartrate and paracetamol in comparison with individual drugs and placebo [Behandlung des Migraneanfalls: die Kombination Dihydroergotamintartrat und Paracetamol im Vergleich zu den Einzelsubstanzen und Placebo]. Medizinische Klinik (Munich)1993;88(11):642‐8. ">Hoernecke 1993</a>). Thirty‐one percent (31%; 89/288) of attacks were pain‐free at two hours with paracetamol 1000 mg compared with 19% (65/288) with placebo (<a href="./references#CD008040-fig-0004" title="">Analysis 1.1</a>). </p> </section> <section id="CD008040-sec-0067"> <h5 class="title">Paracetamol 1000 mg versus dihydroergotamine 2 mg</h5> <p>In addition to providing data for comparison of paracetamol 1000 mg with placebo (above), <a href="./references#CD008040-bbs2-0006" title="HoerneckeR , DoenickeA . Treatment of migraine attacks: combination of dihydroergotamine tartrate and paracetamol in comparison with individual drugs and placebo [Behandlung des Migraneanfalls: die Kombination Dihydroergotamintartrat und Paracetamol im Vergleich zu den Einzelsubstanzen und Placebo]. Medizinische Klinik (Munich)1993;88(11):642‐8. ">Hoernecke 1993</a> also provided data for comparison with dihydroergotamine 2 mg, with medication taken at the onset of attack and the pain not necessarily moderate or severe. Thirty‐one percent (31%; 89/288) of attacks were pain‐free at two hours with paracetamol 1000 mg compared with 25% (72/288) with dihydroergotamine 2 mg. </p> </section> <section id="CD008040-sec-0068"> <h5 class="title">Paracetamol 1000 mg versus etodolac 400 mg and 800 mg</h5> <p>One study provided data for comparison of paracetamol 1000 mg with etodolac 400 mg and 800 mg (<a href="./references#CD008040-bbs2-0010" title="OztürkV , ErtaşM , BaykanB , SirinH , OzgeA , The Mig‐Etol Study Group. Efficacy and safety of 400 and 800 mg etodolac vs. 1,000 mg paracetamol in acute treatment of migraine: a randomized, double‐blind, crossover, multicenter, phase III clinical trial. Pain Practice2012:Epub ahead of print. [DOI: 10.1111/j.1533‐2500.2012.00572.x] ">Oztürk 2012</a>); 19% (64/344) of attacks were pain‐free at two hours with paracetamol 1000 mg compared with 19% (63/327) with etodolac 400 mg and 24% (84/349) with etodolac 800 mg. This study did not have a placebo control group for internal sensitivity. </p> </section> </section> <section id="CD008040-sec-0069"> <h4 class="title">Headache relief at two hours</h4> <section id="CD008040-sec-0070"> <h5 class="title">Paracetamol 1000 mg versus placebo</h5> <p>Three studies (717 participants) provided data for headache relief at two hours when medication was taken for moderate to severe pain (<a href="./references#CD008040-bbs2-0003" title="FreitagF , DiamondM , DiamondS , JanssenI , RodgersA , SkobierandaF . Efficacy and tolerability of coadministration of rizatriptan and acetaminophen vs rizatriptan or acetaminophen alone for acute migraine treatment. Headache2008;48(6):921‐30. [DOI: 10.1111/j.1526‐4610.2007.01053.x] ">Freitag 2008</a>; <a href="./references#CD008040-bbs2-0007" title="LiptonRB , BaggishJS , StewartWF , CodispotiJR , FuM . Efficacy and safety of acetaminophenin the treatment of migraine. Results of a randomized, double‐blind, placebo‐controlled, population‐based study. Archives of Internal Medicine2000;160(22):3486‐92. ">Lipton 2000</a>; <a href="./references#CD008040-bbs2-0011" title="PriorMJ , CodispotiJR , FuM . A randomized, placebo‐controlled trial of acetaminophen for treatment of migraine headache. Headache2010;50(5):819‐33. [DOI: 10.1111/j.1526‐4610.2010.01638.x] ">Prior 2010</a>). </p> <p> <ul id="CD008040-list-0011"> <li> <p>The proportion of participants with headache relief at two hours with paracetamol 1000 mg was 56% (207/367; range 52% to 70%). </p> </li> <li> <p>The proportion of participants with headache relief at two hours with placebo was 36% (127/350; range 32% to 46%). </p> </li> <li> <p>The relative benefit of treatment compared with placebo was 1.6 (1.3 to 1.8); the NNT was 5.0 (3.7 to 7.7) (<a href="./references#CD008040-fig-0006" title="">Analysis 1.3</a>; <a href="#CD008040-fig-0003">Figure 3</a>). </p> </li> </ul> </p> <div class="figure" id="CD008040-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Paracetamol 1000 mg versus placebo, outcome: 1.3 Headache relief at 2 hours." data-id="CD008040-fig-0003" src="/cdsr/doi/10.1002/14651858.CD008040.pub3/media/CDSR/CD008040/image_n/nCD008040-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Paracetamol 1000 mg versus placebo, outcome: 1.3 Headache relief at 2 hours. </p> </div> </div> </div> <p>One other study (<a href="./references#CD008040-bbs2-0006" title="HoerneckeR , DoenickeA . Treatment of migraine attacks: combination of dihydroergotamine tartrate and paracetamol in comparison with individual drugs and placebo [Behandlung des Migraneanfalls: die Kombination Dihydroergotamintartrat und Paracetamol im Vergleich zu den Einzelsubstanzen und Placebo]. Medizinische Klinik (Munich)1993;88(11):642‐8. ">Hoernecke 1993</a>) treated at onset of attack when pain was not necessarily moderate or severe. At two hours, 109/288 (38%) attacks had mild or no pain with paracetamol 1000 mg and 56/288 (20%) with placebo (<a href="./references#CD008040-fig-0006" title="">Analysis 1.3</a>). This cross‐over study reported efficacy data only for participants who treated all four attacks, each with a different intervention. The attrition rate over the course of the study is not known. </p> </section> <section id="CD008040-sec-0071"> <h5 class="title">Paracetamol 1000 mg versus dihydroergotamine 2 mg</h5> <p>One study (<a href="./references#CD008040-bbs2-0006" title="HoerneckeR , DoenickeA . Treatment of migraine attacks: combination of dihydroergotamine tartrate and paracetamol in comparison with individual drugs and placebo [Behandlung des Migraneanfalls: die Kombination Dihydroergotamintartrat und Paracetamol im Vergleich zu den Einzelsubstanzen und Placebo]. Medizinische Klinik (Munich)1993;88(11):642‐8. ">Hoernecke 1993</a>) treated at onset of attack when pain was not necessarily moderate or severe. At two hours, 109/288 (38%) attacks had mild or no pain with paracetamol 1000 mg and 82/288 (28%) with dihydroergotamine 2 mg. This cross‐over study reported efficacy data only for participants who treated all four attacks, each with a different intervention. The attrition rate over the course of the study is not known. </p> </section> <section id="CD008040-sec-0072"> <h5 class="title">Paracetamol 1000 mg versus etodolac 400 mg and 800 mg</h5> <p>One study provided data for comparison of paracetamol 1000 mg with etodolac 400 mg and 800 mg (<a href="./references#CD008040-bbs2-0010" title="OztürkV , ErtaşM , BaykanB , SirinH , OzgeA , The Mig‐Etol Study Group. Efficacy and safety of 400 and 800 mg etodolac vs. 1,000 mg paracetamol in acute treatment of migraine: a randomized, double‐blind, crossover, multicenter, phase III clinical trial. Pain Practice2012:Epub ahead of print. [DOI: 10.1111/j.1533‐2500.2012.00572.x] ">Oztürk 2012</a>); 44% (150/344) of attacks had headache relief at two hours with paracetamol 1000 mg compared with 48% (158/327) with etodolac 400 mg and 46% (161/349) with etodolac 800 mg. This study did not have a placebo control group for internal sensitivity. </p> </section> <section id="CD008040-sec-0073"> <h5 class="title">Paracetamol 500 mg plus domperidone 20 mg versus sumatriptan 50 mg</h5> <p>Only one study provided data for this comparison, with medication taken for moderate to severe pain (<a href="./references#CD008040-bbs2-0002" title="DowsonA , BallK , HaworthD . Comparison of a fixed combination of domperidone and paracetamol (Domperamol) with sumatriptan 50 mg in moderate to severe migraine: a randomised UK primary care study. Current Medical Research and Opinion2000;16(3):190‐7. ">Dowson 2000</a>): 44/120 (36%) of attacks had headache relief at two hours with paracetamol 500 mg plus domperidone 20 mg, compared with 40/120 (33%) with sumatriptan 50 mg. Twenty‐five percent of study participants did not treat both attacks and are not included in any analysis. This study did not have a placebo control group for internal sensitivity and did not report the criteria used for diagnosis. </p> </section> <section id="CD008040-sec-0074"> <h5 class="title">Paracetamol 1000 mg plus metoclopramide 10 mg versus sumatriptan 100 mg</h5> <p>Two studies (1140 participants) provided data for these treatments, with medication taken for moderate to severe pain (<a href="./references#CD008040-bbs2-0004" title="A double‐blind, general practice study to compare GR43175 with paracetamol and metoclopramide in the acute treatment of migraine (Original protocol). 1992. Available at: www.gsk‐clinicalstudyregister.com/. ">GL/MIG/001/92</a>; <a href="./references#CD008040-bbs2-0005" title="A double‐blind, general practice study to compare GR43175 with paracetamol and metoclopramide in the acute treatment of migraine (Amended protocol). 1992. Available at: www.gsk‐clinicalstudyregister.com/. ">GL/MIG/001A/92</a>). Data for the first of three attacks treated are used for this analysis. These studies did not have placebo control groups for internal sensitivity and did not report the criteria used for diagnosis. </p> <p> <ul id="CD008040-list-0012"> <li> <p>The proportion of participants with headache relief at two hours with paracetamol 1000 mg plus metoclopramide 10 mg was 39% (225/580; range 36% to 41%). </p> </li> <li> <p>The proportion of participants with headache relief at two hours with sumatriptan 100 mg was 42% (233/560; range 41% to 42%). </p> </li> <li> <p>The relative benefit of the combination compared with sumatriptan was 0.93 (0.81 to 1.1; <a href="./references#CD008040-fig-0011" title="">Analysis 2.1</a>). The NNT was not calculated. </p> </li> </ul> </p> </section> </section> <section id="CD008040-sec-0075"> <h4 class="title">Headache relief at one hour</h4> <section id="CD008040-sec-0076"> <h5 class="title">Paracetamol 1000 mg versus placebo</h5> <p>Two studies (635 participants) provided data for headache relief at one hour when medication was taken for moderate to severe pain (<a href="./references#CD008040-bbs2-0007" title="LiptonRB , BaggishJS , StewartWF , CodispotiJR , FuM . Efficacy and safety of acetaminophenin the treatment of migraine. Results of a randomized, double‐blind, placebo‐controlled, population‐based study. Archives of Internal Medicine2000;160(22):3486‐92. ">Lipton 2000</a>; <a href="./references#CD008040-bbs2-0011" title="PriorMJ , CodispotiJR , FuM . A randomized, placebo‐controlled trial of acetaminophen for treatment of migraine headache. Headache2010;50(5):819‐33. [DOI: 10.1111/j.1526‐4610.2010.01638.x] ">Prior 2010</a>). </p> <p> <ul id="CD008040-list-0013"> <li> <p>The proportion of participants with headache relief at one hour with paracetamol 1000 mg was 39% (127/324; range 37% to 42%). </p> </li> <li> <p>The proportion of participants with headache relief at one hour with placebo was 20% (62/311; range 17% to 23%). </p> </li> <li> <p>The relative benefit of treatment compared with placebo was 2.0 (1.5 to 2.6; <a href="./references#CD008040-fig-0005" title="">Analysis 1.2</a>); the NNT was 5.2 (3.8 to 8.1). </p> </li> </ul> </p> </section> <section id="CD008040-sec-0077"> <h5 class="title">Paracetamol 1000 mg versus etodolac 400 mg and 800 mg</h5> <p>One study provided data for comparison of paracetamol 1000 mg with etodolac 400 mg and 800 mg (<a href="./references#CD008040-bbs2-0010" title="OztürkV , ErtaşM , BaykanB , SirinH , OzgeA , The Mig‐Etol Study Group. Efficacy and safety of 400 and 800 mg etodolac vs. 1,000 mg paracetamol in acute treatment of migraine: a randomized, double‐blind, crossover, multicenter, phase III clinical trial. Pain Practice2012:Epub ahead of print. [DOI: 10.1111/j.1533‐2500.2012.00572.x] ">Oztürk 2012</a>); 26% (85/327) of attacks had headache relief at one hour with paracetamol 1000 mg compared with 30% (96/321) with etodolac 400 mg and 31% (104/340) with etodolac 800 mg. This study did not have a placebo control group for internal sensitivity, and the reported denominators differ from those reported for 2‐hour outcomes. </p> </section> </section> <section id="CD008040-sec-0078"> <h4 class="title">Sustained pain‐free at 24 hours</h4> <p>Only one study (<a href="./references#CD008040-bbs2-0003" title="FreitagF , DiamondM , DiamondS , JanssenI , RodgersA , SkobierandaF . Efficacy and tolerability of coadministration of rizatriptan and acetaminophen vs rizatriptan or acetaminophen alone for acute migraine treatment. Headache2008;48(6):921‐30. [DOI: 10.1111/j.1526‐4610.2007.01053.x] ">Freitag 2008</a>) comparing paracetamol 1000 mg with placebo and rizatriptan 10 mg reported this outcome; 16% (7/43) of participants had a sustained pain‐free response with paracetamol, 8% (3/39) with placebo, and 23% (10/43) with rizatriptan. </p> </section> <section id="CD008040-sec-0079"> <h4 class="title">Sustained headache relief at 24 hours</h4> <p>Only one study (<a href="./references#CD008040-bbs2-0003" title="FreitagF , DiamondM , DiamondS , JanssenI , RodgersA , SkobierandaF . Efficacy and tolerability of coadministration of rizatriptan and acetaminophen vs rizatriptan or acetaminophen alone for acute migraine treatment. Headache2008;48(6):921‐30. [DOI: 10.1111/j.1526‐4610.2007.01053.x] ">Freitag 2008</a>) comparing paracetamol 1000 mg with placebo and Practipan 10 mg reported this outcome; 42% (18/43) of participants had sustained headache relief with paracetamol, 15% (6/39) with placebo, and 53% (23/43) with rizatriptan. </p> <p>Two studies (<a href="./references#CD008040-bbs2-0004" title="A double‐blind, general practice study to compare GR43175 with paracetamol and metoclopramide in the acute treatment of migraine (Original protocol). 1992. Available at: www.gsk‐clinicalstudyregister.com/. ">GL/MIG/001/92</a>; <a href="./references#CD008040-bbs2-0005" title="A double‐blind, general practice study to compare GR43175 with paracetamol and metoclopramide in the acute treatment of migraine (Amended protocol). 1992. Available at: www.gsk‐clinicalstudyregister.com/. ">GL/MIG/001A/92</a>) comparing paracetamol 1000 mg plus metoclopramide 10 mg with sumatriptan 100 mg reported sustained headache relief at 48 hours; 27% (78/286) experienced the outcome with paracetamol plus metoclopramide and 41% (118/288) with sumatriptan. </p> </section> <section id="CD008040-sec-0080"> <h4 class="title">Subgroup analyses</h4> <p>All included studies used paracetamol at a dose of 1000 mg, but different comparator doses have been analysed separately. There were no data to compare paracetamol with and without an antiemetic, and insufficient data to compare different antiemetics (metoclopramide and domperidone). All medication was administered orally as standard formulations (e.g. not soluble, effervescent). </p> <p>Studies treating at onset of a migraine attack have been analysed separately from those treating once pain is moderate or severe; there were insufficient data for any pooled analysis of studies treating at onset. There were insufficient data for analysis of studies using multiple dosing strategies. </p> </section> <section id="CD008040-sec-0081"> <h4 class="title">Sensitivity analyses</h4> <p>No sensitivity analysis could be carried out for methodological quality or migraine subtype, as all studies scored 3 or more on the Oxford Quality Scale, and no study analysed migraine subtypes separately. </p> <p> <div class="table" id="CD008040-tblf-0001"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>Summary of results A: Pain‐free and headache relief</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Baseline pain intensity</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Studies</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Participants or attacks treated</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Treatment</b> </p> <p><b>(%)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Placebo or comparator</b> </p> <p><b>(%)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR (95% CI)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>NNT</b> </p> <p><b>(95% CI)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pain‐free at 2 h</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Paracetamol 1000 mg versus placebo</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate/severe</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>717</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.8 (1.2 to 2.6)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 (7.5 to 32)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Paracetamol 1000 mg versus placebo</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Onset</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>576</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Paracetamol 1000 mg versus dihydroergotamine 2 mg</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Onset</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>576</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Paracetamol 1000 mg versus etodolac 400 mg</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate/severe</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>671</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Paracetamol 1000 mg versus etodolac 800 mg</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate/severe</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>693</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Headache relief at 2 h</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Paracetamol 1000 mg versus placebo</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate/severe</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>717</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>56</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.6 (1.3 to 1.8)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.0 (3.7 to 7.7)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Paracetamol 1000 mg versus placebo</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Onset</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>576</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Paracetamol 1000 mg versus dihydroergotamine 2 mg</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Onset</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>576</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Paracetamol 1000 mg versus etodolac 400 mg</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate/severe</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>671</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Paracetamol 1000 mg versus etodolac 800 mg</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate/severe</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>693</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Paracetamol 1000 mg + domperidone 20 mg versus sumatriptan 50 mg</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate/severe</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>240</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Paracetamol 1000 mg + metoclopramide 10 mg versus sumatriptan 100 mg</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate/severe</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1140</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.93 (0.81 to 1.1)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not calculated</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Headache relief at 1 h</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Paracetamol 1000 mg versus placebo</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate/severe</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>635</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.0 (1.5 to 2.6)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.2 (3.8 to 8.1)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Paracetamol 1000 mg versus etodolac 400 mg</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate/severe</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>648</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Paracetamol 1000 mg versus etodolac 800 mg</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate/severe</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>667</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> </tbody> </table> </div> </p> </section> <section id="CD008040-sec-0082"> <h4 class="title">Adverse events</h4> <section id="CD008040-sec-0083"> <h5 class="title">Any adverse event</h5> <p>All included studies made some mention of adverse events, but did not always report the numbers of participants in each treatment group who experienced at least one adverse event. The incidence of adverse events varied considerably between studies, and probably reflects whether all events were recorded, or just those that were treatment‐emergent, not part of the migraine attack (i.e. not migraine‐associated symptoms) or considered drug‐related. Differences in the methods used to collect data (e.g. diary vs. spontaneous reporting) may also influence recorded incidence. In addition, it was not always stated whether data continued to be collected after use of rescue medication, which may cause its own adverse events. Where reported, adverse events were described as mostly of mild or moderate intensity, and transient. </p> <p>One study comparing paracetamol 1000 mg with placebo reported the number of participants with at least one adverse event before use of rescue medication and within 24 hours (<a href="./references#CD008040-bbs2-0003" title="FreitagF , DiamondM , DiamondS , JanssenI , RodgersA , SkobierandaF . Efficacy and tolerability of coadministration of rizatriptan and acetaminophen vs rizatriptan or acetaminophen alone for acute migraine treatment. Headache2008;48(6):921‐30. [DOI: 10.1111/j.1526‐4610.2007.01053.x] ">Freitag 2008</a>), two reported within six hours (<a href="./references#CD008040-bbs2-0007" title="LiptonRB , BaggishJS , StewartWF , CodispotiJR , FuM . Efficacy and safety of acetaminophenin the treatment of migraine. Results of a randomized, double‐blind, placebo‐controlled, population‐based study. Archives of Internal Medicine2000;160(22):3486‐92. ">Lipton 2000</a>; <a href="./references#CD008040-bbs2-0011" title="PriorMJ , CodispotiJR , FuM . A randomized, placebo‐controlled trial of acetaminophen for treatment of migraine headache. Headache2010;50(5):819‐33. [DOI: 10.1111/j.1526‐4610.2010.01638.x] ">Prior 2010</a>), and one within two hours (<a href="./references#CD008040-bbs2-0006" title="HoerneckeR , DoenickeA . Treatment of migraine attacks: combination of dihydroergotamine tartrate and paracetamol in comparison with individual drugs and placebo [Behandlung des Migraneanfalls: die Kombination Dihydroergotamintartrat und Paracetamol im Vergleich zu den Einzelsubstanzen und Placebo]. Medizinische Klinik (Munich)1993;88(11):642‐8. ">Hoernecke 1993</a>). These studies were combined for analysis (1293 participants). </p> <p> <ul id="CD008040-list-0014"> <li> <p>The proportion of attacks experiencing adverse events with paracetamol 1000 mg was 18% (117/655; range 1% to 34%). </p> </li> <li> <p>The proportion of attacks experiencing adverse events with placebo was 23% (144/638; range 3% to 46%). </p> </li> <li> <p>The relative risk with treatment compared with placebo was 0.78 (0.64 to 0.95; <a href="./references#CD008040-fig-0007" title="">Analysis 1.4</a>). There were more adverse events with placebo than with paracetamol; the NNTp was 21 (11 to 300) for paracetamol compared with placebo. </p> </li> </ul> </p> <p>In the two studies with high rates of adverse events (<a href="./references#CD008040-bbs2-0007" title="LiptonRB , BaggishJS , StewartWF , CodispotiJR , FuM . Efficacy and safety of acetaminophenin the treatment of migraine. Results of a randomized, double‐blind, placebo‐controlled, population‐based study. Archives of Internal Medicine2000;160(22):3486‐92. ">Lipton 2000</a>; <a href="./references#CD008040-bbs2-0011" title="PriorMJ , CodispotiJR , FuM . A randomized, placebo‐controlled trial of acetaminophen for treatment of migraine headache. Headache2010;50(5):819‐33. [DOI: 10.1111/j.1526‐4610.2010.01638.x] ">Prior 2010</a>), most were migraine‐associated symptoms. </p> <p>One study comparing paracetamol 1000 mg plus metoclopramide 10 mg with sumatriptan 100 mg reported the numbers of participants with "major" and "minor" adverse events (<a href="./references#CD008040-bbs2-0004" title="A double‐blind, general practice study to compare GR43175 with paracetamol and metoclopramide in the acute treatment of migraine (Original protocol). 1992. Available at: www.gsk‐clinicalstudyregister.com/. ">GL/MIG/001/92</a>), and a similar study reported numbers with any adverse events (<a href="./references#CD008040-bbs2-0005" title="A double‐blind, general practice study to compare GR43175 with paracetamol and metoclopramide in the acute treatment of migraine (Amended protocol). 1992. Available at: www.gsk‐clinicalstudyregister.com/. ">GL/MIG/001A/92</a>). We assumed for analysis that major and minor categories are mutually exclusive (which may slightly overestimate the event rate) and combined the studies for analysis. </p> <p> <ul id="CD008040-list-0015"> <li> <p>The proportion of participants experiencing adverse events with paracetamol 1000 mg plus metoclopramide 10 mg was 28% (191/675; range 25% to 32%). </p> </li> <li> <p>The proportion of participants experiencing adverse events with sumatriptan 100 mg was 47% (304/653; range 41% to 53%). </p> </li> <li> <p>The relative risk with paracetamol plus metoclopramide compared with sumatriptan was 0.61 (0.53 to 0.71; <a href="./references#CD008040-fig-0012" title="">Analysis 2.2</a>); the NNTp was 5.5 (4.3 to 7.6) for paracetamol plus metoclopramide compared with sumatriptan. </p> </li> </ul> </p> <p>There were insufficient data for analysis of other comparisons (<a href="./appendices#CD008040-sec-0106">Appendix 6</a>). </p> </section> <section id="CD008040-sec-0084"> <h5 class="title">Specific adverse events</h5> <p>Not all studies reported on numbers of participants with specific adverse events. Some reported the most common events, or those occurring in a given percentage of any treatment arm, while others reported "drug‐related adverse events" or "side effects". Most reported events affected the digestive system (abdominal pain, nausea, vomiting), special senses (sensitivity to stimuli), or the central nervous system (dizziness), and many were likely to be symptoms associated with the migraine attack itself, rather than an adverse effect of the medication. There were too few events for detailed analysis. </p> </section> <section id="CD008040-sec-0085"> <h5 class="title">Serious adverse events</h5> <p>One study (<a href="./references#CD008040-bbs2-0009" title="NørrelundN , ChristiansenLV , PlantenerS . Tolfenamic acid versus paracetamol in migraine attacks. A double‐blind study in general practice [Tolfenamsyre versus paracetamol ved migraeneanfald. En dobbeltblind undersogelse i almen praksis]. Ugeskrift for Laeger1989;151(38):2436‐8. ">Norrelund 1989</a>) did not report on serious adverse events. No study reported any serious adverse events in participants treated with paracetamol 1000 mg alone or paracetamol 1000 mg plus domperidone 20 mg. </p> <p>Two studies comparing paracetamol 1000 mg plus metoclopramide 10 mg or sumatriptan 100 mg (<a href="./references#CD008040-bbs2-0004" title="A double‐blind, general practice study to compare GR43175 with paracetamol and metoclopramide in the acute treatment of migraine (Original protocol). 1992. Available at: www.gsk‐clinicalstudyregister.com/. ">GL/MIG/001/92</a>; <a href="./references#CD008040-bbs2-0005" title="A double‐blind, general practice study to compare GR43175 with paracetamol and metoclopramide in the acute treatment of migraine (Amended protocol). 1992. Available at: www.gsk‐clinicalstudyregister.com/. ">GL/MIG/001A/92</a>) reported on "major" adverse events, which were defined as "serious adverse events or clinical abnormalities that led to withdrawal". These appear to include severe (a measure of intensity) adverse events necessitating withdrawal in addition to any serious events (usually defined as having significant medical consequences such as death, prolonged hospitalisation, permanent disability, or congenital anomaly). </p> <p> <ul id="CD008040-list-0016"> <li> <p>The proportion of participants experiencing major adverse events with paracetamol 1000 mg plus metoclopramide 10 mg was 3% (21/675). </p> </li> <li> <p>The proportion of participants experiencing major adverse events with sumatriptan 100 mg was 6% (41/653; range 5% to 8%). </p> </li> <li> <p>The relative risk with paracetamol plus metoclopramide compared with sumatriptan was 0.50 (0.30 to 0.83; <a href="./references#CD008040-fig-0013" title="">Analysis 2.3</a>); the NNH was 32 (18 to 112). </p> </li> </ul> </p> <p>In <a href="./references#CD008040-bbs2-0004" title="A double‐blind, general practice study to compare GR43175 with paracetamol and metoclopramide in the acute treatment of migraine (Original protocol). 1992. Available at: www.gsk‐clinicalstudyregister.com/. ">GL/MIG/001/92</a> only two types of "major" adverse events were reported by more than 1% of participants: 5/305 reported dizziness and 4/305 reported nausea with sumatriptan 100 mg. One participant reported chest pain with sumatriptan 100 mg. In <a href="./references#CD008040-bbs2-0005" title="A double‐blind, general practice study to compare GR43175 with paracetamol and metoclopramide in the acute treatment of migraine (Amended protocol). 1992. Available at: www.gsk‐clinicalstudyregister.com/. ">GL/MIG/001A/92</a> only one "major" adverse event was reported by more than 1% of participants: 4/348 reported chest pain with sumatriptan 100 mg. There were no "major" adverse events occurring in more than 1% of participants with paracetamol plus metoclopramide in either study. </p> </section> </section> <section id="CD008040-sec-0086"> <h4 class="title">Withdrawals</h4> <section id="CD008040-sec-0087"> <h5 class="title">Adverse event withdrawals</h5> <p>Eight studies reported on withdrawals due to adverse events. In four there were no withdrawals in any treatment arm (<a href="./references#CD008040-bbs2-0003" title="FreitagF , DiamondM , DiamondS , JanssenI , RodgersA , SkobierandaF . Efficacy and tolerability of coadministration of rizatriptan and acetaminophen vs rizatriptan or acetaminophen alone for acute migraine treatment. Headache2008;48(6):921‐30. [DOI: 10.1111/j.1526‐4610.2007.01053.x] ">Freitag 2008</a>; <a href="./references#CD008040-bbs2-0006" title="HoerneckeR , DoenickeA . Treatment of migraine attacks: combination of dihydroergotamine tartrate and paracetamol in comparison with individual drugs and placebo [Behandlung des Migraneanfalls: die Kombination Dihydroergotamintartrat und Paracetamol im Vergleich zu den Einzelsubstanzen und Placebo]. Medizinische Klinik (Munich)1993;88(11):642‐8. ">Hoernecke 1993</a>; <a href="./references#CD008040-bbs2-0007" title="LiptonRB , BaggishJS , StewartWF , CodispotiJR , FuM . Efficacy and safety of acetaminophenin the treatment of migraine. Results of a randomized, double‐blind, placebo‐controlled, population‐based study. Archives of Internal Medicine2000;160(22):3486‐92. ">Lipton 2000</a>; <a href="./references#CD008040-bbs2-0008" title="MacGregorEA , WilkinsonM , BancroftK . Domperidone plus paracetamol in the treatment of migraine. Cephalalgia1993;13(2):124‐7. ">MacGregor 1993</a>). In <a href="./references#CD008040-bbs2-0001" title="DexterSL , GrahamAN , JohnstonES , RatcliffeDM , WilkinsonMI , RoseAJ . Double‐blind controlled study of paramax in the acute treatment of common and classical migraine. British Journal of Clinical Practice1985;39(10):388‐92. ">Dexter 1985</a> there were two withdrawals due to nausea with paracetamol plus metoclopramide, and in <a href="./references#CD008040-bbs2-0011" title="PriorMJ , CodispotiJR , FuM . A randomized, placebo‐controlled trial of acetaminophen for treatment of migraine headache. Headache2010;50(5):819‐33. [DOI: 10.1111/j.1526‐4610.2010.01638.x] ">Prior 2010</a> there were two withdrawals with paracetamol and one with placebo, all due to migraine‐associated symptoms. In <a href="./references#CD008040-bbs2-0004" title="A double‐blind, general practice study to compare GR43175 with paracetamol and metoclopramide in the acute treatment of migraine (Original protocol). 1992. Available at: www.gsk‐clinicalstudyregister.com/. ">GL/MIG/001/92</a> and <a href="./references#CD008040-bbs2-0005" title="A double‐blind, general practice study to compare GR43175 with paracetamol and metoclopramide in the acute treatment of migraine (Amended protocol). 1992. Available at: www.gsk‐clinicalstudyregister.com/. ">GL/MIG/001A/92</a> there were five and eight withdrawals, respectively, with paracetamol plus metoclopramide, and 18 and 13, respectively, with sumatriptan 100 mg, with no reasons for withdrawal given. </p> </section> <section id="CD008040-sec-0088"> <h5 class="title">Other withdrawals and exclusions</h5> <p>Some participants were excluded from analyses because they vomited within 30 minutes of taking study medication, were lost to follow‐up or had major protocol violations. Generally these numbers were small and equally distributed between treatment arms. One four‐period cross‐over study (<a href="./references#CD008040-bbs2-0006" title="HoerneckeR , DoenickeA . Treatment of migraine attacks: combination of dihydroergotamine tartrate and paracetamol in comparison with individual drugs and placebo [Behandlung des Migraneanfalls: die Kombination Dihydroergotamintartrat und Paracetamol im Vergleich zu den Einzelsubstanzen und Placebo]. Medizinische Klinik (Munich)1993;88(11):642‐8. ">Hoernecke 1993</a>) and three studies treating more than one attack with the same medication (<a href="./references#CD008040-bbs2-0001" title="DexterSL , GrahamAN , JohnstonES , RatcliffeDM , WilkinsonMI , RoseAJ . Double‐blind controlled study of paramax in the acute treatment of common and classical migraine. British Journal of Clinical Practice1985;39(10):388‐92. ">Dexter 1985</a>; <a href="./references#CD008040-bbs2-0004" title="A double‐blind, general practice study to compare GR43175 with paracetamol and metoclopramide in the acute treatment of migraine (Original protocol). 1992. Available at: www.gsk‐clinicalstudyregister.com/. ">GL/MIG/001/92</a>; <a href="./references#CD008040-bbs2-0005" title="A double‐blind, general practice study to compare GR43175 with paracetamol and metoclopramide in the acute treatment of migraine (Amended protocol). 1992. Available at: www.gsk‐clinicalstudyregister.com/. ">GL/MIG/001A/92</a>) reported small numbers of participants who withdrew between treatment periods due to lack of efficacy. Lack of efficacy during a single attack should be captured by Use of rescue medication (<a href="./appendices#CD008040-sec-0107">Appendix 7</a>), although there were limited data reported for this outcome. </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD008040-sec-0089" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD008040-sec-0089"></div> <section id="CD008040-sec-0090"> <h3 class="title" id="CD008040-sec-0090">Summary of main results</h3> <p>This review included 11 randomised, double‐blind, controlled studies with 2942 participants (5109 attacks). Medication was taken either at the onset of an attack or once pain intensity was moderate or severe, and most studies investigated the effects of a single dose of medication for an attack. Only one dose of paracetamol, 1000 mg, was used. Five different active comparators were evaluated (sumatriptan 50 mg and 100 mg, dihydroergotamine 2 mg, rizatriptan 25 mg, tolfenamic acid 400 mg, and etodolac 400 mg and 800 mg), plus two in combination with paracetamol (dihydroergotamine and rizatriptan), and two different antiemetics (metoclopramide 10 mg and domperidone 20 and 30 mg) were combined with paracetamol, but there were sufficient data to compare only paracetamol with placebo, and paracetamol plus metoclopramide with sumatriptan. Outcomes were not consistently reported, and only one small study reported on 24‐hour sustained efficacy. There were insufficient data to compare treating an attack at onset with treating once pain has become moderate or severe, or to compare single with multiple dosing regimens. </p> <p>For the IHS preferred outcome of pain‐free at two hours, paracetamol 1000 mg was better than placebo, with an NNT of 12, when baseline pain was moderate or severe (three studies; 717 participants). Around 1 in 5 participants achieved this outcome with paracetamol compared with 1 in 10 with placebo. For headache relief at one hour and two hours, paracetamol was also better than placebo, with NNTs of 5 when baseline pain was moderate or severe. Over half of participants achieved relief at two hours with paracetamol, compared with about 1 in 3 with placebo. </p> <p>There were no data for pain‐free at two hours for the combination of paracetamol 1000 mg and metoclopramide 10 mg versus sumatriptan 100 mg, but for headache relief at two hours, there was no significant difference between the two treatments when baseline pain was moderate or severe (two studies; 1140 participants). About 2 in 5 participants achieved this outcome in these studies. </p> <p>Adverse events were poorly reported, but there was no evidence of an increase in the number of participants experiencing any adverse events with paracetamol 1000 mg compared with placebo, and no serious adverse events were reported with paracetamol alone. Significantly fewer participants experienced any adverse event with the combination of paracetamol plus metoclopramide compared with sumatriptan 1000 mg, and there were more "major" adverse events with sumatriptan (6% versus 3%). </p> <p>Additional analyses (<a href="./appendices#CD008040-sec-0107">Appendix 7</a>) show that for relief of migraine‐associated symptoms of nausea, photophobia and phonophobia, about 10% to 15% more participants achieved relief within two hours with paracetamol than with placebo, with NNTs of 7 to 11. There was no significant difference between paracetamol 1000 mg plus metoclopramide 10 mg and sumatriptan 100 mg for relief of "light/noise sensitivity" at two hours. </p> <p>In the three studies that reported functional disability, most participants were experiencing some degree of disability when they took study medication, and significantly more were free of disability at two hours with paracetamol than with placebo, with an NNT of 10. About 1 in 4 of those with disability at the time of treatment were free of disability at two hours with paracetamol compared with 1 in 7 with placebo. Fewer participants needed to use rescue medication over six hours with paracetamol than with placebo (NNT 6), but more needed it over 24 hours with paracetamol than with sumatriptan (NNH 17). </p> </section> <section id="CD008040-sec-0091"> <h3 class="title" id="CD008040-sec-0091">Overall completeness and applicability of evidence</h3> <p>Included studies did not always report our prespecified outcomes of interest, and for some outcomes (such as adverse events) data were not reported consistently, making it difficult to combine data for analysis. There were insufficient data for most drug comparisons or treatment protocols to allow analysis, so that evidence is limited to the comparison of a single dose of paracetamol (1000 mg) with placebo, and a single dose of the combination of paracetamol plus metoclopramide (1000/10 mg) with sumatriptan 100 mg, both taken when pain intensity was moderate or severe. Even for these comparisons, not all of the prespecified outcomes were reported. Of particular note is that only one small study reported on 24‐hour sustained response (relief or pain‐free) in comparisons with placebo, so that no conclusions can be drawn about whether paracetamol can prevent recurrence of the attack. </p> <p>Participants in most studies had a diagnosis of migraine according to IHS or comparable criteria, but four studies did not report criteria. Of these four, <a href="./references#CD008040-bbs2-0001" title="DexterSL , GrahamAN , JohnstonES , RatcliffeDM , WilkinsonMI , RoseAJ . Double‐blind controlled study of paramax in the acute treatment of common and classical migraine. British Journal of Clinical Practice1985;39(10):388‐92. ">Dexter 1985</a> and <a href="./references#CD008040-bbs2-0002" title="DowsonA , BallK , HaworthD . Comparison of a fixed combination of domperidone and paracetamol (Domperamol) with sumatriptan 50 mg in moderate to severe migraine: a randomised UK primary care study. Current Medical Research and Opinion2000;16(3):190‐7. ">Dowson 2000</a> did not contribute to any efficacy analyses; data for the other two studies (<a href="./references#CD008040-bbs2-0004" title="A double‐blind, general practice study to compare GR43175 with paracetamol and metoclopramide in the acute treatment of migraine (Original protocol). 1992. Available at: www.gsk‐clinicalstudyregister.com/. ">GL/MIG/001/92</a>; <a href="./references#CD008040-bbs2-0005" title="A double‐blind, general practice study to compare GR43175 with paracetamol and metoclopramide in the acute treatment of migraine (Amended protocol). 1992. Available at: www.gsk‐clinicalstudyregister.com/. ">GL/MIG/001A/92</a>) were taken from a manufacturer's Summary of Results sheet, which did not report details of methods, but it is very likely that IHS diagnostic criteria from 1988 were used in these trials. These two studies did provide data for analysis, but it was not possible to compare their results with those from studies that reported diagnostic criteria. </p> <p>Participants were mostly recruited from migraine clinics or primary care, which might lead to under‐representation of individuals with milder headaches. <a href="./references#CD008040-bbs2-0007" title="LiptonRB , BaggishJS , StewartWF , CodispotiJR , FuM . Efficacy and safety of acetaminophenin the treatment of migraine. Results of a randomized, double‐blind, placebo‐controlled, population‐based study. Archives of Internal Medicine2000;160(22):3486‐92. ">Lipton 2000</a> and <a href="./references#CD008040-bbs2-0011" title="PriorMJ , CodispotiJR , FuM . A randomized, placebo‐controlled trial of acetaminophen for treatment of migraine headache. Headache2010;50(5):819‐33. [DOI: 10.1111/j.1526‐4610.2010.01638.x] ">Prior 2010</a> excluded those who usually required bed rest or who vomited during more than 20% of attacks, and <a href="./references#CD008040-bbs2-0011" title="PriorMJ , CodispotiJR , FuM . A randomized, placebo‐controlled trial of acetaminophen for treatment of migraine headache. Headache2010;50(5):819‐33. [DOI: 10.1111/j.1526‐4610.2010.01638.x] ">Prior 2010</a> included only those who had also previously used OTC medications. These two studies contributed almost 90% of the data for the primary outcomes for paracetamol compared with placebo. <a href="./references#CD008040-bbs2-0010" title="OztürkV , ErtaşM , BaykanB , SirinH , OzgeA , The Mig‐Etol Study Group. Efficacy and safety of 400 and 800 mg etodolac vs. 1,000 mg paracetamol in acute treatment of migraine: a randomized, double‐blind, crossover, multicenter, phase III clinical trial. Pain Practice2012:Epub ahead of print. [DOI: 10.1111/j.1533‐2500.2012.00572.x] ">Oztürk 2012</a> excluded those who had severe nausea and/or vomiting for at least 25% of attacks, but did not contribute to analyses. Some individuals with very severe or difficult‐to‐treat migraine headaches may have been excluded in these two studies, and limits on the frequency of attacks would exclude those with very frequent attacks, but otherwise the population in this review was probably representative, in terms of migraine headaches, of those who seek help for the condition. Most studies specified that participants were required to be "in good general health" or excluded those with significant co‐morbidities (including, for example uncontrolled hypertension, renal or hepatic disease, cardiovascular and cerebrovascular disease). This may mean that the population studied may differ from the general public who choose to self‐medicate with OTC paracetamol. </p> <p>The amount of information available for active comparators was small, so that direct comparisons could not be made except for paracetamol plus metoclopramide versus sumatriptan, and there were insufficient data to compare paracetamol plus an antiemetic with placebo. </p> <p>Individual studies are underpowered to determine differences between treatments for adverse events, and even pooling studies may not provide adequate numbers of events to demonstrate differences or allow confidence in the size of the effect. Analysis of adverse events in these studies was further compromised by incomplete and inconsistent reporting, but there was no evidence of increased numbers of adverse events, or any serious adverse events, with paracetamol 1000 mg alone or in combination with metoclopramide 10 mg. </p> </section> <section id="CD008040-sec-0092"> <h3 class="title" id="CD008040-sec-0092">Quality of the evidence</h3> <p>Included studies were of adequate or good methodological quality and validity; reporting of details of the methods of randomisation and allocation concealment tended to be better in more recent studies. </p> </section> <section id="CD008040-sec-0093"> <h3 class="title" id="CD008040-sec-0093">Potential biases in the review process</h3> <p>The main area of concern was that the numbers of participants and events were small and divided between many different comparators. For cross‐over studies we have used data from each phase, which may introduce unknown biases (<a href="./references#CD008040-bbs2-0030" title="ElbourneDR , AltmanDG , HigginsJPT , CurtinF , WorthingtonHV , VailA . Meta‐analyses involving cross‐over trials: methodological issues. International Journal of Epidemiology2002;31(1):140‐9. [DOI: 10.1093/ije/31.1.140] ">Elbourne 2002</a>). </p> <p>We consider that NNTs of 8 for the outcome pain‐free at two hours (13% benefit over comparator), and 6 for headache relief at two hours (17% benefit over comparator), are working limits of clinical utility in this condition. For pain‐free at two hours paracetamol is already outside the limit of utility, so the calculation of the quantity of additional data with null effect that would be required to reach that point could not be done (<a href="./references#CD008040-bbs2-0054" title="MooreRA , BardenJ , DerryS , McQuayHJ . Managing potential publication bias. In: McQuayHJ , KalsoE , MooreRA editor(s). Systematic Reviews in Pain Research: Methodology Refined. Seattle: IASP Press, 2008:15‐24. [ISBN: 978‐0‐931092‐69‐5] ">Moore 2008</a>), and even a small body of unidentified evidence showing no effect would affect interpretation of results for this outcome. For headache relief at two hours we calculate that only 143 participants would be needed in unidentified studies showing no effect of paracetamol over placebo to increase the NNT to the limit of utility. It is not unlikely that this quantity of null data exists. While it is unlikely that the result would be overturned, the size of the effect should be interpreted with caution. </p> </section> <section id="CD008040-sec-0094"> <h3 class="title" id="CD008040-sec-0094">Agreements and disagreements with other studies or reviews</h3> <p>A systematic review of interventions for acute migraine with a literature search to 2000 found no trials using paracetamol that satisfied inclusion criteria and provided primary efficacy data (<a href="./references#CD008040-bbs2-0058" title="OldmanAD , SmithLA , McQuayHJ , MooreRA . Pharmacological treatments for acute migraine: quantitative systematic review. Pain2002;97(3):247‐57. [DOI: 10.1016/S0304‐3959(02)00024‐6] ">Oldman 2002</a>). A review of OTC drugs for acute migraine with a search up to 2002 (<a href="./references#CD008040-bbs2-0075" title="WenzelRG , SarvisCA , KrauseML . Over‐the‐counter drugs for acute migraine attacks: literature review and recommendations. Pharmacotherapy2003;23(4):494‐505. ">Wenzel 2003</a>) found that paracetamol was more effective than placebo for headache relief at two hours, and recommended OTC products (paracetamol, aspirin, ibuprofen and combination products) as "a feasible option" for those who experience disability with fewer than 50% of attacks and/or vomiting with fewer than 20% of attacks. Earlier reviews have also recommended OTC products, together with an antiemetic, for mild migraine attacks (e.g. <a href="./references#CD008040-bbs2-0029" title="DienerHC , KaubeH , LimmrothV . A practical guide to the management and prevention of migraine. Drugs1998;56(5):811‐24. ">Diener 1998</a>). Recent guidelines on the drug treatment of migraine headaches (<a href="./references#CD008040-bbs2-0031" title="EversS , AfraJ , FreseA , GoadsbyPJ , LindeM , MayA , et al. EFNS guideline on the drug treatment of migraine ‐ revised report of an EFNS task force. European Journal of Neurology2009;16(9):968‐81. [DOI: 10.1111/j.1468‐1331.2009.02748.x] ">Evers 2009</a>) acknowledge that paracetamol has shown efficacy in acute treatment in one RCT. This review includes new studies, presenting more robust estimates of efficacy for a number of standard and validated outcomes. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD008040-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008040.pub3/media/CDSR/CD008040/urn:x-wiley:14651858:media:CD008040:CD008040-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008040.pub3/media/CDSR/CD008040/image_t/tCD008040-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies." data-id="CD008040-fig-0001" src="/cdsr/doi/10.1002/14651858.CD008040.pub3/media/CDSR/CD008040/image_n/nCD008040-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008040.pub3/full#CD008040-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008040.pub3/media/CDSR/CD008040/image_n/nCD008040-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008040-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008040.pub3/media/CDSR/CD008040/urn:x-wiley:14651858:media:CD008040:CD008040-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008040.pub3/media/CDSR/CD008040/image_t/tCD008040-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Paracetamol 1000 mg versus placebo, outcome: 1.1 Pain‐free at 2 hours." data-id="CD008040-fig-0002" src="/cdsr/doi/10.1002/14651858.CD008040.pub3/media/CDSR/CD008040/image_n/nCD008040-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Paracetamol 1000 mg versus placebo, outcome: 1.1 Pain‐free at 2 hours. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008040.pub3/full#CD008040-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008040.pub3/media/CDSR/CD008040/image_n/nCD008040-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008040-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008040.pub3/media/CDSR/CD008040/urn:x-wiley:14651858:media:CD008040:CD008040-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008040.pub3/media/CDSR/CD008040/image_t/tCD008040-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Paracetamol 1000 mg versus placebo, outcome: 1.3 Headache relief at 2 hours." data-id="CD008040-fig-0003" src="/cdsr/doi/10.1002/14651858.CD008040.pub3/media/CDSR/CD008040/image_n/nCD008040-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Paracetamol 1000 mg versus placebo, outcome: 1.3 Headache relief at 2 hours. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008040.pub3/full#CD008040-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008040.pub3/media/CDSR/CD008040/image_n/nCD008040-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008040-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008040.pub3/media/CDSR/CD008040/urn:x-wiley:14651858:media:CD008040:CD008040-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008040.pub3/media/CDSR/CD008040/image_t/tCD008040-CMP-001-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Paracetamol 1000 mg versus placebo, Outcome 1 Pain‐free at 2 hours." data-id="CD008040-fig-0004" src="/cdsr/doi/10.1002/14651858.CD008040.pub3/media/CDSR/CD008040/image_n/nCD008040-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Paracetamol 1000 mg versus placebo, Outcome 1 Pain‐free at 2 hours.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008040.pub3/references#CD008040-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008040.pub3/media/CDSR/CD008040/image_n/nCD008040-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008040-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008040.pub3/media/CDSR/CD008040/urn:x-wiley:14651858:media:CD008040:CD008040-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008040.pub3/media/CDSR/CD008040/image_t/tCD008040-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Paracetamol 1000 mg versus placebo, Outcome 2 Headache relief at 1 hour." data-id="CD008040-fig-0005" src="/cdsr/doi/10.1002/14651858.CD008040.pub3/media/CDSR/CD008040/image_n/nCD008040-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Paracetamol 1000 mg versus placebo, Outcome 2 Headache relief at 1 hour.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008040.pub3/references#CD008040-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008040.pub3/media/CDSR/CD008040/image_n/nCD008040-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008040-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008040.pub3/media/CDSR/CD008040/urn:x-wiley:14651858:media:CD008040:CD008040-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008040.pub3/media/CDSR/CD008040/image_t/tCD008040-CMP-001-03.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Paracetamol 1000 mg versus placebo, Outcome 3 Headache relief at 2 hours." data-id="CD008040-fig-0006" src="/cdsr/doi/10.1002/14651858.CD008040.pub3/media/CDSR/CD008040/image_n/nCD008040-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Paracetamol 1000 mg versus placebo, Outcome 3 Headache relief at 2 hours.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008040.pub3/references#CD008040-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008040.pub3/media/CDSR/CD008040/image_n/nCD008040-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008040-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008040.pub3/media/CDSR/CD008040/urn:x-wiley:14651858:media:CD008040:CD008040-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008040.pub3/media/CDSR/CD008040/image_t/tCD008040-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Paracetamol 1000 mg versus placebo, Outcome 4 Any adverse event." data-id="CD008040-fig-0007" src="/cdsr/doi/10.1002/14651858.CD008040.pub3/media/CDSR/CD008040/image_n/nCD008040-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Paracetamol 1000 mg versus placebo, Outcome 4 Any adverse event.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008040.pub3/references#CD008040-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008040.pub3/media/CDSR/CD008040/image_n/nCD008040-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008040-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008040.pub3/media/CDSR/CD008040/urn:x-wiley:14651858:media:CD008040:CD008040-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008040.pub3/media/CDSR/CD008040/image_t/tCD008040-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Paracetamol 1000 mg versus placebo, Outcome 5 Use of rescue medication at 6 h." data-id="CD008040-fig-0008" src="/cdsr/doi/10.1002/14651858.CD008040.pub3/media/CDSR/CD008040/image_n/nCD008040-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Paracetamol 1000 mg versus placebo, Outcome 5 Use of rescue medication at 6 h. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008040.pub3/references#CD008040-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008040.pub3/media/CDSR/CD008040/image_n/nCD008040-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008040-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008040.pub3/media/CDSR/CD008040/urn:x-wiley:14651858:media:CD008040:CD008040-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008040.pub3/media/CDSR/CD008040/image_t/tCD008040-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Paracetamol 1000 mg versus placebo, Outcome 6 Relief of associated symptoms at 2 hours." data-id="CD008040-fig-0009" src="/cdsr/doi/10.1002/14651858.CD008040.pub3/media/CDSR/CD008040/image_n/nCD008040-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Paracetamol 1000 mg versus placebo, Outcome 6 Relief of associated symptoms at 2 hours. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008040.pub3/references#CD008040-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008040.pub3/media/CDSR/CD008040/image_n/nCD008040-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008040-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008040.pub3/media/CDSR/CD008040/urn:x-wiley:14651858:media:CD008040:CD008040-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008040.pub3/media/CDSR/CD008040/image_t/tCD008040-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Paracetamol 1000 mg versus placebo, Outcome 7 Relief of functional disability at 2 hours." data-id="CD008040-fig-0010" src="/cdsr/doi/10.1002/14651858.CD008040.pub3/media/CDSR/CD008040/image_n/nCD008040-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Paracetamol 1000 mg versus placebo, Outcome 7 Relief of functional disability at 2 hours. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008040.pub3/references#CD008040-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008040.pub3/media/CDSR/CD008040/image_n/nCD008040-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008040-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008040.pub3/media/CDSR/CD008040/urn:x-wiley:14651858:media:CD008040:CD008040-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008040.pub3/media/CDSR/CD008040/image_t/tCD008040-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Paracetamol 1000 mg plus metoclopramide 10 mg versus sumatriptan 100 mg, Outcome 1 Headache relief at 2 hours." data-id="CD008040-fig-0011" src="/cdsr/doi/10.1002/14651858.CD008040.pub3/media/CDSR/CD008040/image_n/nCD008040-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Paracetamol 1000 mg plus metoclopramide 10 mg versus sumatriptan 100 mg, Outcome 1 Headache relief at 2 hours. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008040.pub3/references#CD008040-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008040.pub3/media/CDSR/CD008040/image_n/nCD008040-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008040-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008040.pub3/media/CDSR/CD008040/urn:x-wiley:14651858:media:CD008040:CD008040-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008040.pub3/media/CDSR/CD008040/image_t/tCD008040-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Paracetamol 1000 mg plus metoclopramide 10 mg versus sumatriptan 100 mg, Outcome 2 Any adverse event." data-id="CD008040-fig-0012" src="/cdsr/doi/10.1002/14651858.CD008040.pub3/media/CDSR/CD008040/image_n/nCD008040-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Paracetamol 1000 mg plus metoclopramide 10 mg versus sumatriptan 100 mg, Outcome 2 Any adverse event. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008040.pub3/references#CD008040-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008040.pub3/media/CDSR/CD008040/image_n/nCD008040-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008040-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008040.pub3/media/CDSR/CD008040/urn:x-wiley:14651858:media:CD008040:CD008040-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008040.pub3/media/CDSR/CD008040/image_t/tCD008040-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Paracetamol 1000 mg plus metoclopramide 10 mg versus sumatriptan 100 mg, Outcome 3 Major adverse event." data-id="CD008040-fig-0013" src="/cdsr/doi/10.1002/14651858.CD008040.pub3/media/CDSR/CD008040/image_n/nCD008040-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Paracetamol 1000 mg plus metoclopramide 10 mg versus sumatriptan 100 mg, Outcome 3 Major adverse event. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008040.pub3/references#CD008040-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008040.pub3/media/CDSR/CD008040/image_n/nCD008040-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008040-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008040.pub3/media/CDSR/CD008040/urn:x-wiley:14651858:media:CD008040:CD008040-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008040.pub3/media/CDSR/CD008040/image_t/tCD008040-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Paracetamol 1000 mg plus metoclopramide 10 mg versus sumatriptan 100 mg, Outcome 4 Use of rescue medication at 24 h." data-id="CD008040-fig-0014" src="/cdsr/doi/10.1002/14651858.CD008040.pub3/media/CDSR/CD008040/image_n/nCD008040-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Paracetamol 1000 mg plus metoclopramide 10 mg versus sumatriptan 100 mg, Outcome 4 Use of rescue medication at 24 h. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008040.pub3/references#CD008040-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008040.pub3/media/CDSR/CD008040/image_n/nCD008040-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008040-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008040.pub3/media/CDSR/CD008040/urn:x-wiley:14651858:media:CD008040:CD008040-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008040.pub3/media/CDSR/CD008040/image_t/tCD008040-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Paracetamol 1000 mg plus metoclopramide 10 mg versus sumatriptan 100 mg, Outcome 5 Relief of light/noise sensitivity at 2 hours." data-id="CD008040-fig-0015" src="/cdsr/doi/10.1002/14651858.CD008040.pub3/media/CDSR/CD008040/image_n/nCD008040-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 Paracetamol 1000 mg plus metoclopramide 10 mg versus sumatriptan 100 mg, Outcome 5 Relief of light/noise sensitivity at 2 hours. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008040.pub3/references#CD008040-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008040.pub3/media/CDSR/CD008040/image_n/nCD008040-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD008040-tbl-0001"> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Paracetamol 1000 mg compared with placebo for migraine headache</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population: adults with migraine headache ‐ moderate or severe pain</b> </p> <p><b>Settings: community</b> </p> <p><b>Intervention: paracetamol 1000 mg</b> </p> <p><b>Comparison: placebo</b> </p> </td> </tr> <tr class="table-header separated"> <td align="center" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Probable outcome with<br/> intervention</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Probable outcome with<br/> comparator</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>NNT or NNH<br/> (95% CI)</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>No of studies, attacks, events</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pain free response at 2 h</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>190 in 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>100 in 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NNT 12 (7.5 to 32)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 studies, 717 attacks, 104 events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Headache relief at 2 h</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>560 in 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>360 in 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NNT 5.0 (3.7 to 7.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 studies, 717 attacks, 334 events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Headache relief at 1 h</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>390 in 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>200 in 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NNT 5.2 (3.8 to 8.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 studies, 655 attacks, 189 vents</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>At least one AE</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>180 in 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>230 in 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NNH 21 (11 to 300)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 studies, 1293 attacks, 261 events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sustained pain‐free at 24 h</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>no data</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sustained headache relief at 24 h</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>no data</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious AE</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>insufficient data</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>CI:</b> Confidence interval; <b>NNT</b> : number needed to treat; <b>NNH</b>: number needed to harm </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>1 ‐ Quality of evidence downgraded from high because of threat from potential publication bias with modest effect size and numbers of events </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-title"></span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008040.pub3/full#CD008040-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008040-tbl-0002"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Paracetamol 1000 mg versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Pain‐free at 2 hours <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Moderate/severe pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>717</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.80 [1.24, 2.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Onset of attack</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>576</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.37 [1.04, 1.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Headache relief at 1 hour <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Moderate/severe pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>635</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.97 [1.52, 2.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Headache relief at 2 hours <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Moderate/severe pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>717</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.55 [1.32, 1.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Onset of attack</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>576</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.95 [1.47, 2.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Any adverse event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1293</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.64, 0.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Use of rescue medication at 6 h <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>635</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.47, 0.74]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Relief of associated symptoms at 2 hours <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>536</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.37 [1.17, 1.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Photophobia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>985</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.40 [1.19, 1.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 Phonophobia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>944</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.42 [1.21, 1.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Relief of functional disability at 2 hours <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>610</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.76 [1.24, 2.48]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Paracetamol 1000 mg versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008040.pub3/references#CD008040-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008040-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Paracetamol 1000 mg plus metoclopramide 10 mg versus sumatriptan 100 mg</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Headache relief at 2 hours <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.81, 1.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Any adverse event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1328</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.53, 0.71]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Major adverse event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1328</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.30, 0.83]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Use of rescue medication at 24 h <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1243</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [1.01, 1.36]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Relief of light/noise sensitivity at 2 hours <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.85, 1.21]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Paracetamol 1000 mg plus metoclopramide 10 mg versus sumatriptan 100 mg</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008040.pub3/references#CD008040-tbl-0003">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD008040.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD008040-note-0004">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD008040-note-0005">فارسی</a> </li> <li class="section-language"> <a class="" href="ko#CD008040-note-0002">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD008040-note-0003">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="ru#CD008040-note-0001">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD008040-note-0007">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008040\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008040\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008040\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008040\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008040\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008040\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008040\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008040\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008040\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008040\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008040\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008040\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008040\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008040\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008040\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008040\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008040\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008040\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=jiwTpTuf&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008040.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD008040.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD008040.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD008040.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008040.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740725345301"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD008040.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740725345304"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD008040.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e78f29dde936e',t:'MTc0MDcyNTM0NS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 